Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

• Sponsor: GlaxoSmithKline (Industry)
• Overall Status: Completed
• CT.gov ID: NCT02064387
• Collaborator: (none)
• Enrollment: 79
• Locations: 9
• Arms: 4
• Actual Duration (Months): 60.1
• Patients Per Site: 8.8
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 in subjects with multiple myeloma (MM) and lymphomas that express B cell maturation antigen (BCMA). The hypothesis is that GSK2857916 can be safely administered to subjects with MM and with BCMA positive malignancies at doses where target engagement can be demonstrated. This study will determine if adequate target engagement of BCMA receptors translates into clinical benefit for subjects with MM and BCMA positive lymphomas. The study will consists of two parts: a Part 1 dose escalation phase and a Part 2 expansion phase for safety, tolerability, PK, PD, and clinical activity testing. The study will enroll a total of approximately 80-95 subjects with relapsed/refractory MM or BCMA-expressing hematologic malignancies. The maximum dose to be administered in this trial will not exceed 5 milligram/kilogram(mg/kg).

Condition or Disease	Intervention/Treatment	Phase
Multiple Myeloma	Drug: GSK2857916	Phase 1

Study Design

• Study Type: Interventional
• Actual Enrollment: 79 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects With Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA
• Actual Study Start Date: Jul 29, 2014
• Actual Primary Completion Date: Aug 31, 2018
• Actual Study Completion Date: Aug 1, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Schedule 1 Part 1 Participants will receive GSK2857916 intravenously over 60 minutes (one dose) every 3 weeks (21 day cycle) for a maximum of 16 cycles.	Drug: GSK2857916; A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
Experimental: Schedule 2 Part 1 Participants may receive GSK2857916 intravenously over 60 minutes (one dose) once weekly for three consecutive weeks followed by 1 week of rest (28 day cycle) for a maximum of 16 cycles.	Drug: GSK2857916; A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
Experimental: Schedule 1 Part 2 Participants will receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for up to 16 cycles.	Drug: GSK2857916; A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
Experimental: Schedule 2 Part 2 Participants may receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for a maximum of 16 cycles.	Drug: GSK2857916; A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.

Outcome Measures

Primary Outcome Measures

1. Number of Participants With Serious Adverse Events (SAEs) and Common (>=5%) Non-serious Adverse Events- Part 1 [Up to 23.5 months (maximum duration of follow-up from first dose to last contact or death)]

   An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 1 Population comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916. SAEs and common (>=5%) non-SAEs is presented.

2. Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (MM) [Up to 35 months (maximum duration of follow-up from first dose to last contact or death)]

   An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 MM Population comprised of all Part 2 MM participants who received at least one dose of GSK2857916. SAEs and common (>=5%) non-SAEs is presented.

3. Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (NHL) [Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)]

   An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 NHL Population comprised of all Part 2 NHL participants who received at least one dose of GSK2857916. SAEs and common (>=5%) non-SAEs is presented.

4. Number of Participants With Dose-limiting Toxicities (DLTs) During the Determinative Period- Part 1 [Up to Day 21 (from first dose)]

   An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of the following criteria:albuminuria>=2000mgper24 hour which has been confirmed by repeat test at least7 days apart and is not considered to be related to disease progression, Grade4 neutropenia (without fever) lasting>=7 days, febrile neutropenia lasting>=72 hours, Grade>=3 thrombocytopenia associated with bleeding where estimated blood loss is>10 milliliter orGrade4 thrombocytopenia lasting>7 days and not responding to platelet transfusions, anyGrade3 or greaternon-hematologic toxicity as described in Common National Cancer Institute-Terminology Criteria for Adverse Events version4.0 with the exception of the following Grade3 events that can be controlled within48 hours with routine supportive measures and clinically asymptomatic electrolyte abnormalities which can be corrected within48 hours and liver toxicity meeting pre-specified GSK liver stopping criteria.

5. Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 1 [Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)]

   Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), temperature (Temp) and heart rate (HR). SBP and DBP were graded using National Cancer Institute-Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. For SBP: Grade 0-<120 millimeters of mercury[mmHg], 120-139 mmHg[Grade 1], 140-159 mmHg[Grade 2], >=160 mmHg[Grade 3]); For DBP: <80 mmHg [Grade 0], 80-89[Grade 1], 90-99[Grade 2], >=100 mmHg[Grade 3]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

6. Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (MM) [Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)]

   Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-<120 mmHg, 120-139 mmHg[Grade 1], 140-159 mmHg[Grade 2], >=160 mmHg[Grade 3]); For DBP: <80 mmHg [Grade 0], 80-89[Grade 1], 90-99[Grade 2], >=100 mmHg[Grade 3]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

7. Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (NHL) [Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)]

   Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-<120 mmHg, 120-139 mmHg [Grade 1], 140-159 mmHg[Grade 2], >=160 mmHg [Grade 3]); For DBP: <80 mmHg [Grade 0], 80-89[Grade 1], 90-99[Grade 2], >=100 mmHg[Grade 3]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

8. Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 1 [Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)]

   The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to <60 beats per minute [bpm] and increase to >100 bpm) and change in temperature from Baseline (increase to >=38 or decrease to <=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

9. Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM) [Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)]

   The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to <60 bpm and increase to >100 bpm) and change in temperature from Baseline(increase to >=38 or decrease to <=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

10. Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (NHL) [Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)]

    The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to <60 bpm and increase to >100 bpm) and change in temperature from Baseline(increase to >=38 or decrease to <=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

11. Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 [Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)]

    Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (T.Bil.), calcium (Ca), creatinine (Creat), creatinine kinase (CK), gamma glutamyl transferase (GGT), glucose (Gl), potassium (Pot), magnesium (Mg), sodium (Sod), phosphate (Ph) and urate. Values(Hyper and hypo)for Gl, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

12. Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM) [Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)]

    Blood samples were collected for the analysis of following clinical chemistry parameters: albumin,ALP,ALT,AST,T.Bil.,Ca, Creat,CK, GGT,Gl, Pot,Mg, Sod, Ph and urate. Values(Hyper and hypo)for Gl, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

13. Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL) [Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)]

    Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, ALP, ALT, AST, Bilirubin, Ca, Creat, CK, GGT, Glucose, Pot, Mg, Sod, and Ph. Values(Hyper and hypo)for Glucose, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

14. Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1 [Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)]

    Blood samples were collected for the analysis of following clinical chemistry parameters: direct bilirubin (D.Bil.), chloride, carbon dioxide (CO2), lactate dehydrogenase (LDH), total protein (T.Pro) and urea or blood urea nitrogen (BUN). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or No Change (NC)' category. Participants were counted twice if the participant "Decreased to low" and "Increased to high" during post-Baseline. Data for worst-case post Baseline is presented.

15. Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM) [Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)]

    Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, T.Pro and BUN. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data for worst-case post Baseline is presented.

16. Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL) [Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)]

    Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, and T.Pro. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline. Data for worst-case post Baseline is presented.

17. Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 [Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)]

    Blood samples were collected for the analysis of following hematology parameters: hemoglobin (Hb), lymphocytes (Lymph), neutrophils (Neutro), platelet count (PC), and leukocytes (leuko). The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.

18. Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM) [Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)]

    Blood samples were collected for the analysis of following hematology parameters: Hb, Lymph, Neutro, PC, and leuko. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits.An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.

19. Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL) [Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)]

    Blood samples were collected for the analysis of following hematology parameters: Hb, Lymph, Neutro, PC, and leuko. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.

20. Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1 [Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)]

    Blood samples were collected for the analysis of following hematology parameters: basophils (Baso), eosinophils (Eosino), hematocrit (Hct), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), monocytes (Mono), erythrocytes (Erythro) and reticulocytes (Reticu). A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data at worst-case post Baseline is presented.

21. Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM) [Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)]

    Blood samples were collected for the analysis of following hematology parameters: Baso, Eosino, Hct, MCHC, MCH, MCV, Mono, Erythro and Reticu. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data at worst-case post Baseline is presented.

22. Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL) [Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)]

    Blood samples were collected for the analysis of following hematology parameters: Baso, Eosino, Hct, MCHC, MCH, MCV, Mono, Erythro and Reticu. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline. Data at worst-case post Baseline is presented.

23. Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1 [Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)]

    Urine samples were collected to assess urine occult blood (OB) and urine protein (Pro). The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB and no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ for urine Pro indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

24. Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM) [Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)]

    Urine samples were collected to assess urine OB and urine Pro. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB and no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ for urine Pro indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

25. Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL) [Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)]

    Urine samples were collected to assess urine OB and urine Pro. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB. For Urine Pro., results were reported as no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

26. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.06 mg/kg [Baseline and Day 1 (Cycle 2 and 3)]

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

27. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.03 mg/kg and 0.12 mg/kg [Baseline and Day 1 (Cycle 2)]

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

28. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg [Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13,14, 15)]

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

29. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.48 mg/kg [Baseline and Day 1 (Cycle 2, 3, 5, 6, 7, 8)]

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

30. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.96 mg/kg [Baseline and Day 1 (Cycle 2, 3, 4, 5, 6)]

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

31. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg [Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14, 16)]

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

32. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg [Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14, 15, 16)]

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

33. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg [Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)]

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

34. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM) [Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)]

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

35. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (NHL) [Baseline and Day 1 (Cycle 2)]

    Urine samples were collected to assess urine Protein. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Protein excretion (24 hour) is presented.

Secondary Outcome Measures

1. Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1 [Pre-dose, 30 minutes post start of infusion (SOI), at end of infusion (EOI), 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)]

   Blood samples were collected at designated timepoints. Pharmacokinetic (PK) parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

2. AUC[0-infinity] of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg [Pre-dose and EOI of Day 1 (Cycle 1)]

   Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

3. Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1 [Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)]

   Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

4. AUC[0-tau] of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg [Pre-dose and EOI of Day 1 (Cycle 1)]

   Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

5. Area Under the Concentration-time Curve From Zero to Time of Last Quantifiable Concentration (AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1 [Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)]

   Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

6. AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg [Pre-dose and EOI of Day 1 (Cycle 1)]

   Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

7. Clearance (CL) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1 [Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)]

   Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

8. CL of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg [Pre-dose and EOI of Day 1 (Cycle 1)]

   Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

9. Maximum Observed Concentration (Cmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1 [Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)]

   Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

10. Cmax of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg [Pre-dose and EOI of Day 1 (Cycle 1)]

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

11. Trough Plasma Concentration (Ctrough) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1 [Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)]

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

12. Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg [Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)]

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

13. Terminal Half-life (t1/2) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1 [Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)]

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

14. t1/2 of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg [Pre-dose and EOI of Day 1 (Cycle 1)]

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

15. Volume of Distribution at Steady State (Vss) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1 [Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)]

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

16. Vss of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg [Pre-dose and EOI of Day 1 (Cycle 1)]

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

17. Time to Reach Maximum Observed Concentration (Tmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1 [Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)]

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. Median and full range of Tmax have been presented.

18. Tmax of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg [Pre-dose and EOI of Day 1 (Cycle 1)]

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. Median and full range of Tmax have been presented.

19. Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM-Part 2 [Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)]

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

20. Ctrough of GSK2857916 Following IV Dose in Participants With NHL-Part 2 [Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 3)]

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

21. AUC(0-tlast) of Cys Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1 [Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)]

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

22. AUC(0-tlast) of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg [Pre-dose and EOI of Day 1 (Cycle 1)]

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.

23. Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1 [Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)]

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

24. Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg [Pre-dose and EOI of Day 1 (Cycle 1)]

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.

25. Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1 [Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)]

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.

26. Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg [Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)]

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.

27. Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1 [Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)]

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. Median and full range of Tmax have been presented.

28. Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM-Part 1: GSK2857916 2.50 mg/kg [Pre-dose and EOI of Day 1 (Cycle 1)]

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. Median and full range of Tmax have been presented.

29. Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 1 [Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)]

    Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated electrochemiluminescent (ECL) immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.

30. Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (MM) [Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)]

    Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.

31. Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (NHL) [Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)]

    Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated ECLimmunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.

32. Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1 [Baseline, Day 1 (Cycle 2, 3, 4, 6, 9, 12, 16), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)]

    Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive (pos) samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative (neg) conclusive ADA results at Baseline and different timepoints is presented.

33. Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM) [Baseline, Day 1 (Cycle 2, 3, 6, 7, 9, 11, 12, 16), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)]

    Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.

34. Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL) [Baseline, Day 1 (Cycle 2, 3), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)]

    Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.

35. Overall Response Rate (ORR)- Part 1 [From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 21.6 months)]

    ORR was determined by the investigator according to international myeloma working group uniform response criteria for MM (IMWG 2011). ORR was calculated as the number of participants with best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR).

36. ORR-Part 2 (MM) [From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 24.2 months)]

    ORR was determined by the investigator according to IMWG 2011 uniform response criteria for MM. ORR was calculated as the number of participants with best overall response of sCR, CR, VGPR and PR.

37. ORR-Part 2 (NHL) [From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 7.2 months)]

    Overall Response Rate in NHL population was determined by the investigator according to Revised Response Criteria for Malignant Lymphoma. ORR was calculated as the number of participants with confirmed complete remission (CR) or partial remission (PR). Complete remission was defined as disappearance of all evidence of disease and partial remission was defined as regression of measurable disease and no new sites.

38. Clinical Benefit Rate (CBR)- Part 1 [From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 21.6 months)]

    CBR was calculated as the number of participants with best overall response of sCR, CR, VGPR, PR and minimal response (MR).

39. CBR- Part 2 [From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 24.2 months)]

    CBR was calculated as the number of participants with best overall response of sCR, CR, VGPR, PR and MR.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Provide signed written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

• Male or female, 18 years or older (at the time consent is obtained)

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Part 1/dose escalation; Histologically or cytologically confirmed diagnosis of Multiple Myeloma in a subject who fulfills all of the following: has undergone stem cell transplant, or is considered transplant ineligible, has been pretreated with at least the 3 following classes of anti-myeloma drugs: alkylators, proteasome inhibitors and immunomodulators, has demonstrated progression on, or within 60 days of completion of the last therapy.

Part 2 /MM cohort; Histologically or cytologically confirmed diagnosis of: Multiple Myeloma in a subject who fulfills all of the following: has undergone stem cell transplant, or is considered transplant ineligible, has been pretreated with at least the 3 following classes of anti-myeloma drugs: alkylators, proteasome inhibitors and immunomodulators, has demonstrated progression on, or within 60 days of completion of the last therapy, and has measurable disease with at least one of the following: serum M-protein >=0.5 gram (g)/decilitre (dL) (>=5 g/Litre (L)), urine M-protein >=200 milligram (mg)/24hour (h).

Serum free light chain (FLC) assay: Involved FLC level >=5 mg/dL (>=50 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65) and biopsy proven plasmacytoma (should be measured within 28 days of Screening Visit).

• Part 2/Other BCMA positive Hematologic Malignancies cohort: Subject with one of the following lymphomas: Diffuse Large B-cell Lymphoma (DLBCL) or follicular lymphoma (FL) that exhibits positive BCMA expression on tumor cells as determined by a central laboratory using a validated Immunohistochemistry (IHC) assay. Eligible subjects with BCMA positive malignancies must also fulfill the prior treatment requirements as follows: DLBCL: at least 2 prior lines of systemic therapy containing at least one line of chemo-immunotherapy with anti-CD20 antibody, and either has undergone stem cell transplant or is considered transplant ineligible. FL: at least 2 prior lines of systemic therapy.

• Subjects with a history of autologous stem cell transplant are eligible for study participation provided the following eligibility criteria are met: transplant was > 100 days prior to study enrolment, no active infection; subject meets the remainder of the eligibility criteria outlined in the study protocol.

• Adequate organ system functions as defined below Absolute neutrophil count>=1.0x10^{9/L, hemoglobin>=8.0 g/dL, platelet>=50x10}9/L, international normalized ration (INR) <=1.5, Partial thromboplastin time <=1.5xupper limit of normal (ULN), total bilirubin <=1.25xULN, alanine aminotransferase and aspartate aminotransferase<=1.5 X ULN, serum creatinine or calculated creatinine clearance<1.2XULN >=60 mL/min for Part 1;>=50 mL/minute (min) for Part 2 if data supports loosening criteria, Albuminuria<=500 mg/24h, left ventricular ejection fraction >=50%, Troponin<=1xULN, Calcium<=1.1xULN

• A female subject is eligible to participate if she is of: Non-childbearing potential or women of childbearing potential must have a negative serum pregnancy test within 72 hours of first dose of study treatment and agree to use effective contraception during the study and for 60 days following the last dose of study treatment.

• Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from the time of first dose of study until 60 days after the last dose of study treatment to allow for clearance of any altered sperm

• All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events, version 4) must be <=Grade 1 at the time of enrollment except for alopecia, and grade 2 neuropathy.

Exclusion Criteria:

• Systemic anti-tumor therapy within 14 days, or plasmapheresis within 7 days prior to the first dose of study drug

• Use of an investigational drug within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug. Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drug.

• History of an allogeneic stem cell transplant. Subjects with a history of an autologous stem cell transplant are NOT excluded if they meet inclusion criteria related to history of autologous stem cell transplant.

• Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect subject's safety). Subjects with isolated proteinuria resulting from MM are eligible, provided they fulfil the inclusion criteria related to organ system function.

• Evidence of active mucosal or internal bleeding

• Any major surgery within the last four weeks.

• Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures.

• Known active infection requiring antibiotic treatment

• Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal or cardiac disease

• Subjects with previous or concurrent malignancies are allowed only if the second tumor is not contributing to the subject's illness. The subject must not be receiving active therapy, other than hormonal therapy for this disease and the disease must be considered medically stable for at least 2 years.

• Evidence of cardiovascular risk including any of the following: QT interval corrected>=470 millisecond, evidence of current clinically significant uncontrolled arrhythmias, history of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within six months of Screening, Class III or IV heart failure as defined by the New York Heart Association functional classification system, uncontrolled hypertension, subjects with intra-cardiac defibrillators or permanent pacemakers, abnormal cardiac valve morphology (>=grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study.

• Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK2857916 or any of the components of the study treatment.

• Pregnant or lactating female.

• Known human immuno virus infection.

• Subjects with positive test for Hepatitis B surface (HBS-Ag) or Hepatitis B core (HBc)antigen

• Subjects with positive test for hepatitis C (HCV) infection are excluded regardless of viral load. If hepatitis C antibody test is positive, a confirmatory polymerase chain reaction (PCR) or Recombinant immunoblot assay (RIBA) test should be performed. If the PCR or RIBA test is negative, subject is eligible for this trial

• Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease per investigator's assessment).

• Current corneal disease or a history of corneal disease.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	GSK Investigational Site	Boston	Massachusetts	United States	02215
2	GSK Investigational Site	New York	New York	United States	10065
3	GSK Investigational Site	Chapel Hill	North Carolina	United States	27599-7600
4	GSK Investigational Site	Philadelphia	Pennsylvania	United States	19104
5	GSK Investigational Site	Dallas	Texas	United States	75390-8565
6	GSK Investigational Site	Seattle	Washington	United States	98109
7	GSK Investigational Site	Vancouver	British Columbia	Canada	V5Z 1M9
8	GSK Investigational Site	Toronto	Ontario	Canada	M5G 2M9
9	GSK Investigational Site	London		United Kingdom	NW1 2BU

Sponsors and Collaborators

• GlaxoSmithKline

Investigators

• Study Director: GSK Clinical Trials, GlaxoSmithKline

Study Documents (Full-Text)

• Study Protocol - Nov 2, 2017
• Statistical Analysis Plan - Nov 18, 2019

More Information

Publications

• Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Hoos A, Gupta I, Bragulat V, He Z, Opalinska JB, Cohen AD. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019 Mar 20;9(4):37. doi: 10.1038/s41408-019-0196-6.

• Responsible Party: GlaxoSmithKline
• ClinicalTrials.gov Identifier: NCT02064387
• Other Study ID Numbers: 117159; 2013-004549-18
• First Posted: Feb 17, 2014
• Last Update Posted: Aug 11, 2020
• Last Verified: Jul 1, 2020

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Keywords provided by GlaxoSmithKline: Multiple Myeloma; BCMA expressing Lymphomas
• Additional relevant MeSH terms: Multiple Myeloma; Neoplasms, Plasma Cell

Study Results

Participant Flow

Recruitment Details	This is a Phase1 study of antibody drug conjugate GSK2857916 in participants with relapsed/refractory multiple myeloma(MM) or non-hodgkin's lymphoma (NHL).The study was conducted in 2 parts-Part1(dose escalation) and Part2(dose expansion).The starting dose in Part1 was 0.03mg/kg GSK2857916 given once every three weeks; 1cycle=21 days for 16cycles.
Pre-assignment Detail	A total of 79 participants were enrolled (38 participants in Part-1 and 41 participants in Part-2).

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg	Part 2: GSK2857916 3.40 mg/kg (MM)	Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days)
Period Title: Part 1 Max 23.5 Months Followup Duration
STARTED	1	1	4	4	4	3	4	8	3	6	0	0
COMPLETED	1	1	4	4	4	3	4	6	2	5	0	0
NOT COMPLETED	0	0	0	0	0	0	0	2	1	1	0	0
Period Title: Part 1 Max 23.5 Months Followup Duration
STARTED	0	0	0	0	0	0	0	0	0	0	35	6
COMPLETED	0	0	0	0	0	0	0	0	0	0	29	3
NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	6	3

Baseline Characteristics

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg	Part 2: GSK2857916 3.40 mg/kg (MM)	Part 2: GSK2857916 3.40 mg/kg (NHL)	Total
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days)	Total of all reporting groups
Overall Participants	1	1	4	4	4	3	4	8	3	6	35	6	79
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	49.0 (NA)	71.0 (NA)	56.5 (3.32)	58.5 (8.35)	60.0 (10.89)	58.7 (13.05)	65.3 (4.79)	62.6 (11.04)	48.0 (8.19)	54.8 (10.11)	60.5 (7.93)	60.2 (9.81)	59.6 (8.90)
Sex: Female, Male (Count of Participants)
Female	1 100%	0 0%	3 75%	2 50%	2 50%	1 33.3%	2 50%	5 62.5%	1 33.3%	1 16.7%	18 51.4%	3 50%	39 49.4%
Male	0 0%	1 100%	1 25%	2 50%	2 50%	2 66.7%	2 50%	3 37.5%	2 66.7%	5 83.3%	17 48.6%	3 50%	40 50.6%
Race/Ethnicity, Customized (Count of Participants)
Black or African American	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	4 50%	0 0%	0 0%	5 14.3%	0 0%	10 12.7%
Arabic/North African Heritage	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	1 16.7%	0 0%	0 0%	2 2.5%
White/Caucasian/European Heritage	1 100%	1 100%	4 100%	3 75%	4 100%	3 100%	3 75%	4 50%	3 100%	5 83.3%	28 80%	6 100%	65 82.3%
Japanese Heritage	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 2.9%	0 0%	1 1.3%
South East Asian Heritage	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 2.9%	0 0%	1 1.3%

Outcome Measures

1. Primary Outcome

Title	Number of Participants With Serious Adverse Events (SAEs) and Common (>=5%) Non-serious Adverse Events- Part 1
Description	An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 1 Population comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916. SAEs and common (>=5%) non-SAEs is presented.
Time Frame	Up to 23.5 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 1 Population

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	8	3	6
Common non-SAE	1 100%	1 100%	4 100%	4 100%	3 75%	3 100%	4 100%	8 100%	3 100%	6 100%
Any SAE	0 0%	0 0%	1 25%	1 25%	1 25%	0 0%	2 50%	4 50%	1 33.3%	3 50%

2. Primary Outcome

Title	Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (MM)
Description	An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 MM Population comprised of all Part 2 MM participants who received at least one dose of GSK2857916. SAEs and common (>=5%) non-SAEs is presented.
Time Frame	Up to 35 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 MM Population

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (MM)
Arm/Group Description	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
Measure Participants	35
Common non-SAE	35 3500%
Any SAE	17 1700%

3. Primary Outcome

Title	Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (NHL)
Description	An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 NHL Population comprised of all Part 2 NHL participants who received at least one dose of GSK2857916. SAEs and common (>=5%) non-SAEs is presented.
Time Frame	Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 NHL Population

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days)
Measure Participants	6
Common non-SAE	6 600%
Any SAE	3 300%

4. Primary Outcome

Title	Number of Participants With Dose-limiting Toxicities (DLTs) During the Determinative Period- Part 1
Description	An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of the following criteria:albuminuria>=2000mgper24 hour which has been confirmed by repeat test at least7 days apart and is not considered to be related to disease progression, Grade4 neutropenia (without fever) lasting>=7 days, febrile neutropenia lasting>=72 hours, Grade>=3 thrombocytopenia associated with bleeding where estimated blood loss is>10 milliliter orGrade4 thrombocytopenia lasting>7 days and not responding to platelet transfusions, anyGrade3 or greaternon-hematologic toxicity as described in Common National Cancer Institute-Terminology Criteria for Adverse Events version4.0 with the exception of the following Grade3 events that can be controlled within48 hours with routine supportive measures and clinically asymptomatic electrolyte abnormalities which can be corrected within48 hours and liver toxicity meeting pre-specified GSK liver stopping criteria.
Time Frame	Up to Day 21 (from first dose)

Outcome Measure Data

Analysis Population Description

DLT Evaluable Population(pop) in Part 1 comprised of All Treated Pop (participants who received at least 1 dose of study treatment) and who received a complete infusion in cycle 1 (once every 3 weeks dosing). Any Part 1 participant in the"All Treated" pop who experiences a DLT, will also be included in the DLT evaluable pop regardless of exposure.

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	8	3	6
Count of Participants [Participants]	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%

5. Primary Outcome

Title	Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 1
Description	Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), temperature (Temp) and heart rate (HR). SBP and DBP were graded using National Cancer Institute-Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. For SBP: Grade 0-<120 millimeters of mercury[mmHg], 120-139 mmHg[Grade 1], 140-159 mmHg[Grade 2], >=160 mmHg[Grade 3]); For DBP: <80 mmHg [Grade 0], 80-89[Grade 1], 90-99[Grade 2], >=100 mmHg[Grade 3]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 1 Population

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	8	3	6
DBP, any grade increase	0 0%	1 100%	2 50%	1 25%	2 50%	3 100%	3 75%	5 62.5%	3 100%	4 66.7%
SBP, any grade increase	0 0%	1 100%	2 50%	2 50%	3 75%	1 33.3%	3 75%	7 87.5%	2 66.7%	5 83.3%

6. Primary Outcome

Title	Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (MM)
Description	Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-<120 mmHg, 120-139 mmHg[Grade 1], 140-159 mmHg[Grade 2], >=160 mmHg[Grade 3]); For DBP: <80 mmHg [Grade 0], 80-89[Grade 1], 90-99[Grade 2], >=100 mmHg[Grade 3]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 MM Population

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (MM)
Arm/Group Description	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
Measure Participants	35
DBP, any grade increase	30 3000%
SBP, any grade increase	31 3100%

7. Primary Outcome

Title	Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (NHL)
Description	Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-<120 mmHg, 120-139 mmHg [Grade 1], 140-159 mmHg[Grade 2], >=160 mmHg [Grade 3]); For DBP: <80 mmHg [Grade 0], 80-89[Grade 1], 90-99[Grade 2], >=100 mmHg[Grade 3]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time Frame	Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 NHL Population

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days)
Measure Participants	6
DBP, any grade increase	5 500%
SBP, any grade increase	5 500%

8. Primary Outcome

Title	Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 1
Description	The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to <60 beats per minute [bpm] and increase to >100 bpm) and change in temperature from Baseline (increase to >=38 or decrease to <=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 1 Population

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	8	3	6
HR, decrease to <60	0 0%	0 0%	2 50%	1 25%	0 0%	0 0%	1 25%	4 50%	1 33.3%	3 50%
HR, change to normal or no change	0 0%	0 0%	0 0%	2 50%	1 25%	0 0%	1 25%	3 37.5%	1 33.3%	1 16.7%
HR, increase to >100	1 100%	1 100%	2 50%	1 25%	3 75%	3 100%	2 50%	1 12.5%	1 33.3%	2 33.3%
Temp, decrease to <=35	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Temp, change to normal or no change	1 100%	1 100%	3 75%	4 100%	4 100%	2 66.7%	4 100%	8 100%	2 66.7%	6 100%
Temp, increase to >=38	0 0%	0 0%	1 25%	0 0%	0 0%	1 33.3%	0 0%	0 0%	1 33.3%	0 0%

9. Primary Outcome

Title	Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM)
Description	The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to <60 bpm and increase to >100 bpm) and change in temperature from Baseline(increase to >=38 or decrease to <=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 MM Population

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (MM)
Arm/Group Description	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
Measure Participants	35
HR, decrease to <60	9 900%
HR, change to normal or no change	17 1700%
HR, increase to >100	10 1000%
Temp, decrease to <=35	1 100%
Temp, change to normal or no change	29 2900%
Temp, increase to >=38	5 500%

10. Primary Outcome

Title	Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (NHL)
Description	The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to <60 bpm and increase to >100 bpm) and change in temperature from Baseline(increase to >=38 or decrease to <=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 NHL Population

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days)
Measure Participants	6
HR, decrease to <60	3 300%
HR, change to normal or no change	2 200%
HR, increase to >100	1 100%
Temp, decrease to <=35	0 0%
Temp, change to normal or no change	5 500%
Temp, increase to >=38	1 100%

11. Primary Outcome

Title	Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Description	Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (T.Bil.), calcium (Ca), creatinine (Creat), creatinine kinase (CK), gamma glutamyl transferase (GGT), glucose (Gl), potassium (Pot), magnesium (Mg), sodium (Sod), phosphate (Ph) and urate. Values(Hyper and hypo)for Gl, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	8	3	6
Gl, Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	1 25%	1 25%	4 100%	0 0%	4 100%	6 75%	0 0%	4 66.7%
Gl, Hyper,increase toGrade 3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	2 50%	0 0%	0 0%	0 0%
Gl, Hyper,increase toGrade 4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Gl, Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	1 12.5%	0 0%	2 33.3%
Gl, Hypo,increase toGrade 3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Gl, Hypo,increase toGrade 4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Albumin,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	1 25%	2 50%	3 75%	1 33.3%	1 25%	1 12.5%	1 33.3%	2 33.3%
Albumin,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Albumin,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
ALP,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	1 25%	1 25%	0 0%	1 25%	2 25%	2 66.7%	5 83.3%
ALP,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
ALP,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
ALT,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	1 25%	2 50%	1 25%	0 0%	1 25%	5 62.5%	1 33.3%	5 83.3%
ALT,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
ALT,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
AST,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	1 100%	2 50%	2 50%	1 25%	1 33.3%	3 75%	6 75%	3 100%	5 83.3%
AST,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
AST,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
T.Bil.,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	2 66.7%	0 0%
T.Bil.,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
T.Bil.,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
CK,any grade increase,n=1,1,4,4,3,3,4,8,3,6	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	3 37.5%	3 100%	3 50%
CK,increase to Grade 3,n=1,1,4,4,3,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 12.5%	0 0%	0 0%
CK,increase to Grade 4,n=1,1,4,4,3,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Creat,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	2 50%	0 0%	1 25%	1 33.3%	1 25%	0 0%	0 0%	0 0%
Creat,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Creat,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
GGT,any grade increase,1,1,4,4,3,3,4,8,3,6	0 0%	0 0%	1 25%	1 25%	1 25%	0 0%	3 75%	3 37.5%	3 100%	4 66.7%
GGT,increase to Grade 3,n=1,1,4,4,3,3,4,8,3,6	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	1 12.5%	0 0%	0 0%
GGT,increase to Grade 4,n=1,1,4,4,3,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Pot,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Pot,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Pot,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Pot,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	1 25%	1 25%	1 25%	2 66.7%	0 0%	1 12.5%	1 33.3%	2 33.3%
Pot,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Pot,Hypo,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Mg,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Mg,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Mg,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Mg,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	1 25%	0 0%	1 25%	0 0%	0 0%	3 37.5%	0 0%	3 50%
Mg,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Mg,Hypo,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Ph,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	2 50%	1 25%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%
Ph,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Ph,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Sod,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 12.5%	0 0%	0 0%
Sod,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Sod,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Sod,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	1 100%	1 25%	2 50%	2 50%	1 33.3%	3 75%	2 25%	0 0%	3 50%
Sod,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	2 33.3%
Sod,Hypo,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Urate,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	1 100%	0 0%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%
Urate,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Urate,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6	0 0%	1 100%	0 0%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%
Ca,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	1 25%	0 0%	1 25%	1 33.3%	3 75%	2 25%	0 0%	1 16.7%
Ca,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%
Ca,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Ca,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	2 66.7%	1 16.7%
Ca,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Ca,Hypo,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%

12. Primary Outcome

Title	Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Description	Blood samples were collected for the analysis of following clinical chemistry parameters: albumin,ALP,ALT,AST,T.Bil.,Ca, Creat,CK, GGT,Gl, Pot,Mg, Sod, Ph and urate. Values(Hyper and hypo)for Gl, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 MM Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (MM)
Arm/Group Description	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
Measure Participants	35
Gl, Hyperglycemia,any grade increase,n=35	19 1900%
Gl, Hyperglycemia,increase to Grade 3,n=35	0 0%
Gl, Hyperglycemia,increase to Grade 4,n=35	0 0%
Gl, Hypoglycemia,any grade increase,n=35	1 100%
Gl, Hypoglycemia,increase to Grade 3,n=35	0 0%
Gl, Hypoglycemia,increase to Grade 4,n=35	0 0%
Albumin,any grade increase,n=35	15 1500%
Albumin,increase to Grade 3,n=35	2 200%
Albumin,increase to Grade 4,n=35	0 0%
ALP,any grade increase,n=35	19 1900%
ALP,increase to Grade 3,n=35	0 0%
ALP,increase to Grade 4,,n=35	0 0%
ALT,any grade increase,n=35	19 1900%
ALT,increase to Grade 3,n=35	0 0%
ALT,increase to Grade 4,n=35	0 0%
AST,any grade increase,n=35	29 2900%
AST,increase to Grade 3,n=35	3 300%
AST,increase to Grade 4,n=35	0 0%
Total bilirubin,any grade increase,n=35	3 300%
Total bilirubin,increase to Grade 3,n=35	0 0%
Total bilirubin,increase to Grade 4,n=35	0 0%
CK,any grade increase,n=35	15 1500%
CK,increase to Grade 3,n=35	1 100%
CK,increase to Grade 4 ,n=35	0 0%
Creatinine,any grade increase,n=35	7 700%
Creatinine,increase to Grade 3,n=35	0 0%
Creatinine,increase to Grade 4,n=35	0 0%
GGT,any grade increase,n=34	21 2100%
GGT,increase to Grade 3,n=34	6 600%
GGT,increase to Grade 4,n=34	0 0%
Pot,Hyperkalemia,any grade increase,n=35	1 100%
Pot,Hyperkalemia,increase to Grade 3,n=35	0 0%
Pot,Hyperkalemia,increase to Grade 4,n=35	1 100%
Pot,Hypokalemia,any grade increase,n=35	12 1200%
Pot,Hypokalemia,increase to Grade 3,n=35	3 300%
Pot,Hypokalemia,increase to Grade 4,n=35	1 100%
Mg,Hypermagnesemia,any grade increase,n=34	1 100%
Mg,Hypermagnesemia,increase to Grade 3,n=34	0 0%
Mg,Hypermagnesemia,increase to Grade 4,n=34	0 0%
Mg,Hypomagnesemia,any grade increase,n=34	9 900%
Mg,Hypomagnesemia,increase to Grade 3,n=34	0 0%
Mg,Hypomagnesemia,increase to Grade 4,n=34	1 100%
Phosphate,any grade increase,n=35	8 800%
Phosphate,increase to Grade 3,n=35	0 0%
Phosphate,increase to Grade 4,n=35	0 0%
Sod,Hypernatremia,any grade increase,n=35	0 0%
Sod,Hypernatremia,increase to Grade 3,n=35	0 0%
Sod,Hypernatremia,increase to Grade 4,n=35	0 0%
Sod,Hyponatremia,any grade increase,n=35	4 400%
Sod,Hyponatremia,increase to Grade 3,n=35	0 0%
Sod,Hyponatremia,increase to Grade 4,n=35	1 100%
Urate,any grade increase,n=35	1 100%
Urate,increase to Grade 3,n=35	0 0%
Urate,increase to Grade 4,n=35	1 100%
Ca,Hypercalcemia,any grade increase,n=35	8 800%
Ca,Hypercalcemia,increase to Grade 3,n=35	2 200%
Ca,Hypercalcemia,increase to Grade 4,,n=35	1 100%
Ca,Hypocalcemia,any grade increase,n=35	4 400%
Ca,Hypocalcemia,increase to Grade 3,n=35	0 0%
Ca,Hypocalcemia,increase to Grade 4,n=35	0 0%

13. Primary Outcome

Title	Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Description	Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, ALP, ALT, AST, Bilirubin, Ca, Creat, CK, GGT, Glucose, Pot, Mg, Sod, and Ph. Values(Hyper and hypo)for Glucose, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).
Measure Participants	5
Gl, Hyperglycemia,any grade increase	2 200%
Gl, Hyperglycemia,increase to Grade 3	0 0%
Gl, Hyperglycemia,increase to Grade 4	0 0%
Gl, Hypoglycemia,any grade increase	0 0%
Gl, Hypoglycemia,increase to Grade 3	0 0%
Gl, Hypoglycemia,increase to Grade 4	0 0%
Albumin,any grade increase	2 200%
Albumin,increase to Grade 3	0 0%
Albumin,increase to Grade 4	0 0%
ALP,any grade increase	1 100%
ALP,increase to Grade 3	0 0%
ALP,increase to Grade 4	0 0%
ALT,any grade increase	1 100%
ALT,increase to Grade 3	0 0%
ALT,increase to Grade 4	0 0%
AST,any grade increase	2 200%
AST,increase to Grade 3	0 0%
AST,increase to Grade 4	0 0%
Total bilirubin,any grade increase	2 200%
Total bilirubin,increase to Grade 3	0 0%
Total bilirubin,increase to Grade 4	0 0%
CK,any grade increase	1 100%
CK,increase to Grade 3	0 0%
CK,increase to Grade 4	0 0%
Creatinine,any grade increase	1 100%
Creatinine,increase to Grade 3	0 0%
Creatinine,increase to Grade 4	0 0%
GGT,any grade increase	2 200%
GGT,increase to Grade 3	0 0%
GGT,increase to Grade 4	0 0%
Pot,Hyperkalemia,any grade increase	0 0%
Pot,Hyperkalemia,increase to Grade 3	0 0%
Pot,Hyperkalemia,increase to Grade 4	0 0%
Pot,Hypokalemia,any grade increase	1 100%
Pot,Hypokalemia,increase to Grade 3	0 0%
Pot,Hypokalemia,increase to Grade 4	0 0%
Mg,Hypermagnesemia,any grade increase	0 0%
Mg,Hypermagnesemia,increase to Grade 3	0 0%
Mg,Hypermagnesemia,increase to Grade 4	0 0%
Mg,Hypomagnesemia,any grade increase	1 100%
Mg,Hypomagnesemia,increase to Grade 3	0 0%
Mg,Hypomagnesemia,increase to Grade 4	0 0%
Phosphate,any grade increase	2 200%
Phosphate,increase to Grade 3	1 100%
Phosphate,increase to Grade 4	0 0%
Sod,Hypernatremia,any grade increase	0 0%
Sod,Hypernatremia,increase to Grade 3	0 0%
Sod,Hypernatremia,increase to Grade 4	0 0%
Sod,Hyponatremia,any grade increase	3 300%
Sod,Hyponatremia,increase to Grade 3	0 0%
Sod,Hyponatremia,increase to Grade 4	0 0%
Ca,Hypercalcemia,any grade increase	4 400%
Ca,Hypercalcemia,increase to Grade 3	1 100%
Ca,Hypercalcemia,increase to Grade 4	0 0%
Ca,Hypocalcemia,any grade increase	1 100%
Ca,Hypocalcemia,increase to Grade 3	0 0%
Ca,Hypocalcemia,increase to Grade 4	0 0%

14. Primary Outcome

Title	Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
Description	Blood samples were collected for the analysis of following clinical chemistry parameters: direct bilirubin (D.Bil.), chloride, carbon dioxide (CO2), lactate dehydrogenase (LDH), total protein (T.Pro) and urea or blood urea nitrogen (BUN). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or No Change (NC)' category. Participants were counted twice if the participant "Decreased to low" and "Increased to high" during post-Baseline. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	8	3	6
D.Bil.,decrease to low,n=1,1,4,2,2,3,4,4,3,5	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 12.5%	0 0%	1 16.7%
D.Bil.,to normal or NC, n=1,1,4,2,2,3,4,4,3,5	1 100%	1 100%	3 75%	2 50%	1 25%	3 100%	4 100%	3 37.5%	3 100%	3 50%
D.Bil.,increase to high,n=1,1,4,2,2,3,4,4,3,5	0 0%	0 0%	1 25%	0 0%	1 25%	0 0%	0 0%	0 0%	0 0%	2 33.3%
Chloride,decrease to low,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	1 25%	0 0%	2 50%	1 33.3%	1 25%	3 37.5%	0 0%	3 50%
Chloride,to normal or NC,n=1,1,4,4,4,3,4,8,3,6	1 100%	1 100%	3 75%	4 100%	2 50%	2 66.7%	3 75%	4 50%	2 66.7%	3 50%
Chloride,increase to high,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 12.5%	1 33.3%	0 0%
CO2,decrease to low,n=1,1,4,4,4,3,4,8,3,6	1 100%	1 100%	1 25%	3 75%	1 25%	1 33.3%	3 75%	2 25%	2 66.7%	2 33.3%
CO2, to normal or NC,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	3 75%	1 25%	3 75%	2 66.7%	0 0%	5 62.5%	1 33.3%	4 66.7%
CO2,increase to high,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	1 12.5%	0 0%	0 0%
LDH,decrease to low,n=1,1,4,4,3,3,4,8,3,6	0 0%	0 0%	0 0%	1 25%	1 25%	0 0%	0 0%	0 0%	0 0%	0 0%
LDH,to normal or NC,n=n=1,1,4,4,3,3,4,8,3,6	1 100%	1 100%	2 50%	2 50%	1 25%	2 66.7%	1 25%	5 62.5%	1 33.3%	1 16.7%
LDH,increase to high,n=1,1,4,4,3,3,4,8,3,6	0 0%	0 0%	2 50%	1 25%	1 25%	1 33.3%	3 75%	3 37.5%	2 66.7%	5 83.3%
T.Pro,decrease to low,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	2 25%	2 66.7%	0 0%
T.Pro,to normal or NC,n=1,1,4,4,4,3,4,8,3,6	1 100%	1 100%	4 100%	3 75%	2 50%	2 66.7%	3 75%	6 75%	1 33.3%	4 66.7%
T.Pro,increase to high,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	2 50%	1 33.3%	1 25%	0 0%	0 0%	2 33.3%
BUN,decrease to low,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	1 25%	0 0%	2 50%	0 0%	0 0%	1 12.5%	0 0%	2 33.3%
BUN,to normal or NC,n=1,1,4,4,4,3,4,8,3,6	1 100%	1 100%	2 50%	3 75%	2 50%	3 100%	3 75%	5 62.5%	2 66.7%	3 50%
BUN,increase to high,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	1 25%	1 25%	0 0%	0 0%	1 25%	2 25%	1 33.3%	1 16.7%

15. Primary Outcome

Title	Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
Description	Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, T.Pro and BUN. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 MM Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (MM)
Arm/Group Description	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
Measure Participants	35
D.Bil.,decrease to low,n=30	2 200%
D.Bil., to normal or no change,n=30	20 2000%
D.Bil.,increase to high,n=30	8 800%
Chloride,decrease to low,n=35	7 700%
Chloride, to normal or no change,n=35	25 2500%
Chloride,increase to high,n=35	4 400%
CO2,decrease to low,n=35	8 800%
CO2, to normal or no change,n=35	23 2300%
CO2,increase to high,n=35	5 500%
LDH,decrease to low,n=35	1 100%
LDH, to normal or no change,n=35	17 1700%
LDH,increase to high,n=35	17 1700%
T.Pro,decrease to low,n=35	11 1100%
T.Pro, to normal or no change,n=35	18 1800%
T.Pro,increase to high,n=35	7 700%
BUN,decrease to low,n=35	8 800%
BUN, to normal or no change,n=35	23 2300%
BUN,increase to high,n=35	4 400%

16. Primary Outcome

Title	Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
Description	Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, and T.Pro. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days)
Measure Participants	5
D.Bil.,decrease to low,n=2	0 0%
D.Bil., to normal or no change,n=2	2 200%
D.Bil.,increase to high,n=2	0 0%
Chloride,decrease to low,n=5	1 100%
Chloride, to normal or no change,n=5	2 200%
Chloride,increase to high,n=5	2 200%
CO2,decrease to low,n=5	2 200%
CO2, to normal or no change,n=5	3 300%
CO2,increase to high,n=5	0 0%
LDH,decrease to low,n=5	0 0%
LDH, to normal or no change,n=5	4 400%
LDH,increase to high,n=5	1 100%
T.Pro,decrease to low,n=5	1 100%
T.Pro, to normal or no change,n=5	4 400%
T.Pro,increase to high,n=5	0 0%

17. Primary Outcome

Title	Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Description	Blood samples were collected for the analysis of following hematology parameters: hemoglobin (Hb), lymphocytes (Lymph), neutrophils (Neutro), platelet count (PC), and leukocytes (leuko). The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 1 Population

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	8	3	6
Hb, Hb increased, any grade increase	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 33.3%	0 0%
Hb, Hb increased, increase to Grade 3	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Hb, Hb increased, increase to Grade 4	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Hb,Anemia, any grade increase	1 100%	1 100%	1 25%	2 50%	2 50%	2 66.7%	1 25%	3 37.5%	2 66.7%	4 66.7%
Hb, Anemia, increase to Grade 3	0 0%	1 100%	1 25%	1 25%	1 25%	1 33.3%	0 0%	0 0%	0 0%	1 16.7%
Hb, Anemia, increase to Grade 4	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Lymph, Lymph count increased, any grade increase	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Lymph, Lymph count increased, increase to Grade 3	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Lymph, Lymph count increased, increase to Grade 4	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Lymph, Lymph count decreased, any grade increase	0 0%	0 0%	1 25%	0 0%	2 50%	1 33.3%	2 50%	4 50%	2 66.7%	3 50%
Lymph, Lymph count decreased, increase to Grade 3	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	4 50%	0 0%	1 16.7%
Lymph, Lymph count decreased, increase to Grade 4	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	0 0%	2 33.3%
Neutro, any grade increase	1 100%	1 100%	2 50%	1 25%	0 0%	2 66.7%	1 25%	4 50%	2 66.7%	3 50%
Neutro, increase to Grade 3	0 0%	1 100%	1 25%	1 25%	0 0%	0 0%	0 0%	0 0%	1 33.3%	0 0%
Neutro, increase to Grade 4	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 16.7%
PC, any grade increase	1 100%	1 100%	2 50%	3 75%	1 25%	1 33.3%	2 50%	6 75%	3 100%	6 100%
PC, increase to Grade 3	1 100%	0 0%	0 0%	2 50%	0 0%	1 33.3%	0 0%	0 0%	2 66.7%	4 66.7%
PC, increase to Grade 4	0 0%	0 0%	1 25%	0 0%	1 25%	0 0%	0 0%	0 0%	0 0%	1 16.7%
Leuko, Leukocytosis, any grade increase	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Leuko, Leukocytosis, increase to Grade 3	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Leuko, Leukocytosis, increase to Grade 4	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Leuko, Leuko decreased, any grade increase	1 100%	1 100%	3 75%	1 25%	1 25%	1 33.3%	3 75%	1 12.5%	2 66.7%	3 50%
Leuko, Leuko decreased, increase to Grade 3	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	2 33.3%
Leuko, Leuko decreased, increase to Grade 4	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%

18. Primary Outcome

Title	Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Description	Blood samples were collected for the analysis of following hematology parameters: Hb, Lymph, Neutro, PC, and leuko. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits.An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 MM Population

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (MM)
Arm/Group Description	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
Measure Participants	35
Hb, Hb increased, any grade increase	1 100%
Hb, Hb increased, increase to Grade 3	0 0%
Hb, Hb increased, increase to Grade 4	0 0%
Hb,Anemia, any grade increase	18 1800%
Hb, Anemia, increase to Grade 3	7 700%
Hb, Anemia, increase to Grade 4	0 0%
Lymph, Lymph count increased, any grade increase	3 300%
Lymph, Lymph count increased, increase to Grade 3	0 0%
Lymph, Lymph count increased, increase to Grade 4	0 0%
Lymph, Lymph count decreased, any grade increase	18 1800%
Lymph, Lymph count decreased, increase to Grade 3	8 800%
Lymph, Lymph count decreased, increase to Grade 4	2 200%
Neutro, any grade increase	15 1500%
Neutro, increase to Grade 3	2 200%
Neutro, increase to Grade 4	5 500%
PC, any grade increase	32 3200%
PC, increase to Grade 3	13 1300%
PC, increase to Grade 4	3 300%
Leuko, Leukocytosis, any grade increase	0 0%
Leuko, Leukocytosis, increase to Grade 3	0 0%
Leuko, Leukocytosis, increase to Grade 4	0 0%
Leuko, Leuko decreased, any grade increase	16 1600%
Leuko, Leuko decreased, increase to Grade 3	4 400%
Leuko, Leuko decreased, increase to Grade 4	1 100%

19. Primary Outcome

Title	Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Description	Blood samples were collected for the analysis of following hematology parameters: Hb, Lymph, Neutro, PC, and leuko. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).
Measure Participants	6
Hb, Hb increased, any grade increase, n=6	0 0%
Hb, Hb increased, increase to Grade 3, n=6	0 0%
Hb, Hb increased, increase to Grade 4, n=6	0 0%
Hb,Anemia, any grade increase, n=6	2 200%
Hb, Anemia, increase to Grade 3, n=6	0 0%
Hb, Anemia, increase to Grade 4, n=6	0 0%
Lymph,Lymph count increased,any grade increase,n=6	0 0%
Lymph,Lymph count increased,increase to Grade3,n=6	0 0%
Lymph,Lymph count increased,increase to Grade4,n=6	0 0%
Lymph,Lymph count decreased,any grade increase,n=6	5 500%
Lymph,Lymph count decreased,increase to Grade3,n=6	3 300%
Lymph,Lymph count decreased,increase to Grade4,n=6	2 200%
Neutro, any grade increase, n=6	0 0%
Neutro, increase to Grade 3, n=6	0 0%
Neutro, increase to Grade 4, n=6	0 0%
PC, any grade increase, n=5	3 300%
PC, increase to Grade 3, n=5	0 0%
PC, increase to Grade 4, n=5	1 100%
Leuko, Leukocytosis, any grade increase, n=6	0 0%
Leuko, Leukocytosis, increase to Grade 3, n=6	0 0%
Leuko, Leukocytosis, increase to Grade 4, n=6	0 0%
Leuko, Leuko decreased, any grade increase, n=6	4 400%
Leuko, Leuko decreased, increase to Grade 3, n=6	0 0%
Leuko, Leuko decreased, increase to Grade 4, n=6	0 0%

20. Primary Outcome

Title	Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Description	Blood samples were collected for the analysis of following hematology parameters: basophils (Baso), eosinophils (Eosino), hematocrit (Hct), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), monocytes (Mono), erythrocytes (Erythro) and reticulocytes (Reticu). A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data at worst-case post Baseline is presented.
Time Frame	Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	8	3	6
Baso,decrease to low,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	2 33.3%
Baso, to normal or NC,n=1,1,4,4,4,3,4,8,3,6	1 100%	1 100%	4 100%	4 100%	4 100%	3 100%	3 75%	8 100%	3 100%	3 50%
Baso,increase to high,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	3 50%
Eosino,decrease to low,n=1,1,4,4,4,3,4,8,3,6	1 100%	0 0%	1 25%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	1 16.7%
Eosino,to normal or NC,n=1,1,4,4,4,3,4,8,3,6	0 0%	1 100%	3 75%	4 100%	4 100%	2 66.7%	4 100%	8 100%	3 100%	4 66.7%
Eosino,increase to high,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	2 33.3%
Hct,decrease to low,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	1 25%	0 0%	1 33.3%	0 0%	1 12.5%	1 33.3%	0 0%
Hct, to normal or NC,n=1,1,4,4,4,3,4,8,3,6	1 100%	1 100%	4 100%	3 75%	4 100%	2 66.7%	4 100%	7 87.5%	1 33.3%	6 100%
Hct,increase to high,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 33.3%	0 0%
MCH,decrease to low,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	3 75%	3 37.5%	1 33.3%	1 16.7%
MCH, to normal or NC,n=1,1,4,4,4,3,4,8,3,6	1 100%	1 100%	4 100%	4 100%	3 75%	3 100%	1 25%	5 62.5%	2 66.7%	5 83.3%
MCH,increase to high,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	1 12.5%	0 0%	0 0%
MCHC,decrease to low,n=1,1,4,4,4,3,4,8,3,6	0 0%	1 100%	0 0%	0 0%	0 0%	1 33.3%	1 25%	3 37.5%	1 33.3%	1 16.7%
MCHC, to normal or NC,n=1,1,4,4,4,3,4,8,3,6	1 100%	0 0%	4 100%	3 75%	4 100%	2 66.7%	3 75%	5 62.5%	2 66.7%	5 83.3%
MCHC,increase to high,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
MCV,decrease to low,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	2 50%	0 0%	1 33.3%	1 16.7%
MCV, to normal or NC,n=1,1,4,4,4,3,4,8,3,6	1 100%	0 0%	4 100%	4 100%	4 100%	3 100%	2 50%	8 100%	2 66.7%	5 83.3%
MCV,increase to high,n=1,1,4,4,4,3,4,8,3,6	0 0%	1 100%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Mono,decrease to low,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 12.5%	0 0%	0 0%
Mono, to normal or NC,n=1,1,4,4,4,3,4,8,3,6	0 0%	1 100%	3 75%	3 75%	4 100%	3 100%	2 50%	5 62.5%	0 0%	1 16.7%
Mono,increase to high,n=1,1,4,4,4,3,4,8,3,6	1 100%	0 0%	1 25%	1 25%	0 0%	0 0%	2 50%	3 37.5%	3 100%	5 83.3%
Erythro,decrease to low,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	2 25%	0 0%	0 0%
Erythro, to normal or NC,n=1,1,4,4,4,3,4,8,3,6	1 100%	1 100%	4 100%	4 100%	4 100%	3 100%	3 75%	6 75%	2 66.7%	6 100%
Erythro,increase to high,n=1,1,4,4,4,3,4,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	1 33.3%	0 0%
Reticu,decrease to low,n=1,1,3,3,2,1,4,8,2,6	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	0 0%	3 37.5%	1 33.3%	1 16.7%
Reticu,to normal or NC,n=1,1,3,3,2,1,4,8,2,6	1 100%	1 100%	1 25%	3 75%	1 25%	0 0%	1 25%	4 50%	1 33.3%	4 66.7%
Reticu,increase to high,n=1,1,3,3,2,1,4,8,2,6	0 0%	0 0%	1 25%	0 0%	1 25%	1 33.3%	3 75%	1 12.5%	0 0%	1 16.7%

21. Primary Outcome

Title	Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Description	Blood samples were collected for the analysis of following hematology parameters: Baso, Eosino, Hct, MCHC, MCH, MCV, Mono, Erythro and Reticu. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data at worst-case post Baseline is presented.
Time Frame	Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 MM Population.Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (MM)
Arm/Group Description	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
Measure Participants	35
Baso,decrease to low,n=35	0 0%
Baso, to normal or NC,n=35	33 3300%
Baso,increase to high,n=35	2 200%
Eosino,decrease to low,n=35	7 700%
Eosino,to normal or NC,n=35	26 2600%
Eosino,increase to high,n=35	2 200%
Hct,decrease to low,n=35	4 400%
Hct, to normal or NC,n=35	31 3100%
Hct,increase to high,n=35	0 0%
MCH,decrease to low,n=35	7 700%
MCH, to normal or NC,n=35	28 2800%
MCH,increase to high,n=35	1 100%
MCHC,decrease to low,n=35	5 500%
MCHC, to normal or NC,n=35	28 2800%
MCHC,increase to high,n=35	2 200%
MCV,decrease to low,n=35	6 600%
MCV, to normal or NC,n=35	28 2800%
MCV,increase to high,n=35	1 100%
Mono,decrease to low,n=35	4 400%
Mono, to normal or NC,n=35	18 1800%
Mono,increase to high,n=35	14 1400%
Erythro,decrease to low,n=35	2 200%
Erythro, to normal or NC,n=35	31 3100%
Erythro,increase to high,n=35	2 200%
Reticu,decrease to low,n=28	10 1000%
Reticu, to normal or NC,n=28	14 1400%
Reticu,increase to high,n=28	8 800%

22. Primary Outcome

Title	Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Description	Blood samples were collected for the analysis of following hematology parameters: Baso, Eosino, Hct, MCHC, MCH, MCV, Mono, Erythro and Reticu. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline. Data at worst-case post Baseline is presented.
Time Frame	Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).
Measure Participants	6
Baso,decrease to low,n=6	0 0%
Baso, to normal or NC,n=6	6 600%
Baso,increase to high,n=6	0 0%
Eosino,decrease to low,n=6	0 0%
Eosino,to normal or NC,n=6	6 600%
Eosino,increase to high,n=6	0 0%
Hct,decrease to low,n=6	1 100%
Hct, to normal or NC,n=6	5 500%
Hct,increase to high,n=6	0 0%
MCH,decrease to low,n=6	1 100%
MCH, to normal or NC,n=6	5 500%
MCH,increase to high,n=6	0 0%
MCHC,decrease to low,n=6	1 100%
MCHC, to normal or NC,n=6	5 500%
MCHC,increase to high,n=6	0 0%
MCV,decrease to low,n=6	2 200%
MCV, to normal or NC,n=6	4 400%
MCV,increase to high,n=6	0 0%
Mono,decrease to low,n=6	0 0%
Mono, to normal or NC,n=6	4 400%
Mono,increase to high,n=6	2 200%
Erythro,decrease to low,n=6	2 200%
Erythro, to normal or NC,n=6	4 400%
Erythro,increase to high,n=6	0 0%
Reticu,decrease to low,n=5	0 0%
Reticu, to normal or NC,n=5	4 400%
Reticu,increase to high,n=5	1 100%

23. Primary Outcome

Title	Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1
Description	Urine samples were collected to assess urine occult blood (OB) and urine protein (Pro). The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB and no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ for urine Pro indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	8	3	6
OB,No change/decreased, n=1,1,4,4,2,3,3,8,3,6	1 100%	1 100%	3 75%	3 75%	1 25%	2 66.7%	1 25%	5 62.5%	2 66.7%	5 83.3%
OB,Increase to small, n=1,1,4,4,2,3,3,8,3,6	0 0%	0 0%	1 25%	0 0%	1 25%	1 33.3%	2 50%	3 37.5%	1 33.3%	0 0%
OB,Increase to moderate, n=1,1,4,4,2,3,3,8,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
OB,Increase to large, n=1,1,4,4,2,3,3,8,3,6	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	0 0%	0 0%	1 16.7%
Pro,No change/decreased, n=1,1,4,3,2,3,4,5,3,5	1 100%	0 0%	3 75%	3 75%	2 50%	1 33.3%	3 75%	1 12.5%	1 33.3%	1 16.7%
Pro,Increase to trace, n=1,1,4,3,2,3,4,5,3,5	0 0%	0 0%	1 25%	0 0%	0 0%	1 33.3%	0 0%	4 50%	2 66.7%	1 16.7%
Pro,Increase to 1+, n=1,1,4,3,2,3,4,5,3,5	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	1 16.7%
Pro,Increase to 2+, n=1,1,4,3,2,3,4,5,3,5	0 0%	0 0%	0 0%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	1 16.7%
Pro,Increase to 3+, n=1,1,4,3,2,3,4,5,3,5	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Pro,Unknown, n=1,1,4,3,2,3,4,5,3,5	0 0%	1 100%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 16.7%

24. Primary Outcome

Title	Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)
Description	Urine samples were collected to assess urine OB and urine Pro. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB and no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ for urine Pro indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 MM Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (MM)
Arm/Group Description	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
Measure Participants	35
OB,No change/decreased, n=33	18 1800%
OB,Increase to small, n=33	14 1400%
OB,Increase to moderate, n=33	1 100%
OB,Increase to large, n=33	0 0%
Pro,No change/decreased, n=31	15 1500%
Pro,Increase to trace, n=31	11 1100%
Pro,Increase to 1+, n=31	1 100%
Pro,Increase to 2+, n=31	0 0%
Pro,Increase to 3+, n=31	0 0%
Pro,Unknown, n=31	4 400%

25. Primary Outcome

Title	Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)
Description	Urine samples were collected to assess urine OB and urine Pro. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB. For Urine Pro., results were reported as no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time Frame	Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days)
Measure Participants	5
OB,No change/decreased, n=5	4 400%
OB,Increase to small, n=5	0 0%
OB,Increase to moderate, n=5	0 0%
OB,Increase to large, n=5	1 100%
Pro,No change/decreased, n=4	3 300%
Pro,Increase to trace, n=4	1 100%
Pro,Increase to 1+, n=4	0 0%
Pro,Increase to 2+, n=4	0 0%
Pro,Increase to 3+, n=4	0 0%

26. Primary Outcome

Title	Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.06 mg/kg
Description	Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time Frame	Baseline and Day 1 (Cycle 2 and 3)

Outcome Measure Data

Analysis Population Description

Part 1 Population. NA indicates that standard deviation could not be calculated for a single participant.

Arm/Group Title	Part 1: GSK2857916 0.06 mg/kg
Arm/Group Description	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1
Day 1 (Cycle 2)	-0.0 (NA)
Day 1 (Cycle 3)	0.3 (NA)

27. Primary Outcome

Title	Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.03 mg/kg and 0.12 mg/kg
Description	Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time Frame	Baseline and Day 1 (Cycle 2)

Outcome Measure Data

Analysis Population Description

Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.03 mg/kg
Arm/Group Description	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	3	0
Mean (Standard Deviation) [Grams per day]	0.4 (0.72)

28. Primary Outcome

Title	Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Description	Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time Frame	Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13,14, 15)

Outcome Measure Data

Analysis Population Description

Part 1 Population. Only those participants with data available at the specified data points were analyzed. NA indicates that standard deviation could not be calculated for a single participant.

Arm/Group Title	Part 1: GSK2857916 0.24 mg/kg
Arm/Group Description	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1
Day 1 (Cycle 2)	-0.0 (NA)
Day 1 (Cycle 3)	-0.0 (NA)
Day 1 (Cycle 4)	88.1 (NA)
Day 1 (Cycle 5)	-0.1 (NA)
Day 1 (Cycle 6)	-0.0 (NA)
Day 1 (Cycle 7)	-0.0 (NA)
Day 1 (Cycle 8)	-0.1 (NA)
Day 1 (Cycle 9)	-0.1 (NA)
Day 1 (Cycle 10)	-0.1 (NA)
Day 1 (Cycle 12)	-0.1 (NA)
Day 1 (Cycle 13)	-0.1 (NA)
Day 1 (Cycle 14)	-0.1 (NA)
Day 1 (Cycle 15)	-0.1 (NA)

29. Primary Outcome

Title	Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.48 mg/kg
Description	Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time Frame	Baseline and Day 1 (Cycle 2, 3, 5, 6, 7, 8)

Outcome Measure Data

Analysis Population Description

Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). NA indicates that standard deviation could not be calculated for a single participant.

Arm/Group Title	Part 1: GSK2857916 0.48 mg/kg
Arm/Group Description	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	4
Day 1 (Cycle 2), n=2	0.0 (0.04)
Day 1 (Cycle 3), n=1	0.8 (NA)
Day 1 (Cycle 5), n=1	0.1 (NA)
Day 1 (Cycle 6), n=1	0.1 (NA)
Day 1 (Cycle 7), n=1	0.1 (NA)
Day 1 (Cycle 8), n=1	0.1 (NA)

30. Primary Outcome

Title	Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.96 mg/kg
Description	Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time Frame	Baseline and Day 1 (Cycle 2, 3, 4, 5, 6)

Outcome Measure Data

Analysis Population Description

Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). NA indicates that standard deviation could not be calculated for a single participant.

Arm/Group Title	Part 1: GSK2857916 0.96 mg/kg
Arm/Group Description	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	3
Day 1 (Cycle 2), n=2	0.2 (0.35)
Day 1 (Cycle 3), n=2	-0.1 (0.07)
Day 1 (Cycle 4), n=1	-0.1 (NA)
Day 1 (Cycle 5), n=1	0.0 (NA)
Day 1 (Cycle 6), n=1	0.2 (NA)

31. Primary Outcome

Title	Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Description	Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time Frame	Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14, 16)

Outcome Measure Data

Analysis Population Description

Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). NA indicates that standard deviation could not be calculated for a single participant.

Arm/Group Title	Part 1: GSK2857916 1.92 mg/kg
Arm/Group Description	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	4
Day 1 (Cycle 2), n=3	-0.1 (0.48)
Day 1 (Cycle 3), n=3	-30.3 (51.72)
Day 1 (Cycle 4), n=4	-22.4 (45.06)
Day 1 (Cycle 5), n=3	0.2 (1.42)
Day 1 (Cycle 6), n=2	-0.6 (0.99)
Day 1 (Cycle 7), n=2	-0.6 (1.16)
Day 1 (Cycle 8), n=2	-0.6 (1.06)
Day 1 (Cycle 11), n=1	-1.4 (NA)
Day 1 (Cycle 12), n=1	-1.4 (NA)
Day 1 (Cycle 13), n=1	-1.4 (NA)
Day 1 (Cycle 14), n=1	-1.4 (NA)
Day 1 (Cycle 16), n=1	-1.3 (NA)

32. Primary Outcome

Title	Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Description	Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time Frame	Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14, 15, 16)

Outcome Measure Data

Analysis Population Description

Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). NA indicates that standard deviation could not be calculated for a single participant.

Arm/Group Title	Part 1: GSK2857916 2.50 mg/kg
Arm/Group Description	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	8
Day 1 (Cycle 2), n=4	0.8 (1.54)
Day 1 (Cycle 3), n=2	-0.2 (0.31)
Day 1 (Cycle 4), n=2	-0.2 (0.38)
Day 1 (Cycle 5), n=1	0.0 (NA)
Day 1 (Cycle 6), n=2	-0.2 (0.33)
Day 1 (Cycle 7), n=1	0.2 (NA)
Day 1 (Cycle 8), n=1	-0.5 (NA)
Day 1 (Cycle 10), n=1	-0.4 (NA)
Day 1 (Cycle 12), n=1	-0.5 (NA)
Day 1 (Cycle 13), n=1	-0.5 (NA)
Day 1 (Cycle 14), n=1	-0.4 (NA)
Day 1 (Cycle 15), n=1	-0.5 (NA)
Day 1 (Cycle 16), n=1	-0.5 (NA)

33. Primary Outcome

Title	Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Description	Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time Frame	Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

Outcome Measure Data

Analysis Population Description

Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). NA indicates that standard deviation could not be calculated for a single participant.

Arm/Group Title	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	3	6
Day 1 (Cycle 2), n=2,5	-0.6 (0.83)	0.0 (0.45)
Day 1 (Cycle 3), n=2,4	-0.6 (0.81)	-0.0 (0.23)
Day 1 (Cycle 4), n=2,4	-0.7 (0.79)	-0.1 (0.25)
Day 1 (Cycle 5), n=2,4	-0.6 (0.78)	-0.1 (0.46)
Day 1 (Cycle 6), n=2,4	-0.6 (0.80)	-0.0 (0.33)
Day 1 (Cycle 7), n=2,4	-0.6 (0.79)	-0.1 (0.48)
Day 1 (Cycle 8), n=2,2	-0.6 (0.80)	0.1 (0.15)
Day 1 (Cycle 9), n=1,2	-1.1 (NA)	0.2 (0.33)
Day 1 (Cycle 10), n=1,2	-1.1 (NA)	-0.0 (0.03)
Day 1 (Cycle 11), n=1,2	-1.2 (NA)	-0.1 (0.06)
Day 1 (Cycle 12), n=1,2	-1.2 (NA)	0.0 (0.13)
Day 1 (Cycle 13), n=1,2	-1.1 (NA)	0.0 (0.09)
Day 1 (Cycle 14), n=1,2	-1.0 (NA)	0.3 (0.11)
Day 1 (Cycle 15), n=1,2	-1.1 (NA)	0.1 (0.10)
Day 1 (Cycle 16), n=1,2	-1.2 (NA)	0.4 (0.11)

34. Primary Outcome

Title	Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Description	Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time Frame	Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

Outcome Measure Data

Analysis Population Description

Part 2 MM Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (MM)
Arm/Group Description	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
Measure Participants	35
Day 1 (Cycle 2), n=24	-0.5 (1.21)
Day 1 (Cycle 3), n=18	-0.7 (1.29)
Day 1 (Cycle 4), n=13	-0.7 (1.65)
Day 1 (Cycle 5), n=15	-0.7 (1.66)
Day 1 (Cycle 6), n=14	-0.8 (1.69)
Day 1 (Cycle 7), n=14	-0.9 (1.56)
Day 1 (Cycle 8), n=16	-0.7 (1.53)
Day 1 (Cycle 9), n=13	-0.5 (1.01)
Day 1 (Cycle 10), n=12	-0.4 (1.06)
Day 1 (Cycle 11), n=10	-0.4 (1.01)
Day 1 (Cycle 12), n=10	-0.4 (1.11)
Day 1 (Cycle 13), n=9	-0.4 (1.27)
Day 1 (Cycle 14), n=9	-0.4 (1.25)
Day 1 (Cycle 15), n=9	-0.4 (1.30)
Day 1 (Cycle 16), n=9	-0.3 (1.35)

35. Primary Outcome

Title	Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (NHL)
Description	Urine samples were collected to assess urine Protein. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Protein excretion (24 hour) is presented.
Time Frame	Baseline and Day 1 (Cycle 2)

Outcome Measure Data

Analysis Population Description

Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).
Measure Participants	2
Mean (Standard Deviation) [Grams per day]	0.0 (0.18)

36. Secondary Outcome

Title	Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1
Description	Blood samples were collected at designated timepoints. Pharmacokinetic (PK) parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time Frame	Pre-dose, 30 minutes post start of infusion (SOI), at end of infusion (EOI), 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population comprised of Part 1 participants of All Treated Population who had atleast 1 non-missing (non-quantifiable, NQ values were considered non-missing) PK assessment. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0	1	4	3	3	2	1	0	4
Geometric Mean (Geometric Coefficient of Variation) [Hours*nanogram per milliliter]	215803.06 (NA)	767285.51 (49.51)	632339.28 (101.14)	2991509.97 (72.12)	9235256.20 (46.65)	18469186.92 (NA)	8355209.26 (25.29)

37. Secondary Outcome

Title	AUC[0-infinity] of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 2.50 mg/kg
Arm/Group Description	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0

38. Secondary Outcome

Title	Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time Frame	Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0	1	4	4	3	3	3	2	6
Geometric Mean (Geometric Coefficient of Variation) [Hours*nanogram per milliliter]	200467.82 (NA)	633446.78 (35.42)	729443.84 (91.22)	2389114.19 (51.12)	4448319.69 (79.51)	9892863.42 (51.81)	23121531.16 (6.59)	9738914.76 (38.82)

39. Secondary Outcome

Title	AUC[0-tau] of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 2.50 mg/kg
Arm/Group Description	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0

40. Secondary Outcome

Title	Area Under the Concentration-time Curve From Zero to Time of Last Quantifiable Concentration (AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time Frame	Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	3	3	3	3	6
Geometric Mean (Geometric Coefficient of Variation) [Hours*nanogram per milliliter]	44260.79 (NA)	178485.20 (NA)	637783.48 (35.67)	694825.13 (107.50)	2170746.96 (59.81)	4492292.65 (82.00)	10093784.72 (54.20)	19239850.61 (53.15)	10131666.86 (47.32)

41. Secondary Outcome

Title	AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 2.50 mg/kg
Arm/Group Description	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0

42. Secondary Outcome

Title	Clearance (CL) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time Frame	Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0	1	4	3	3	2	1	0	4
Geometric Mean (Geometric Coefficient of Variation) [Milliliter per hour]	28.27 (NA)	10.53 (58.94)	25.01 (88.61)	15.10 (75.16)	8.46 (27.46)	11.68 (NA)	38.84 (37.53)

43. Secondary Outcome

Title	CL of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 2.50 mg/kg
Arm/Group Description	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0

44. Secondary Outcome

Title	Maximum Observed Concentration (Cmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time Frame	Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	3	3	3	3	6
Geometric Mean (Geometric Coefficient of Variation) [Nanograms per milliliter]	429.00 (NA)	1323.00 (NA)	2956.77 (18.45)	4548.10 (20.27)	11876.46 (24.08)	23050.05 (23.05)	43774.18 (45.18)	68128.02 (20.84)	117385.57 (24.14)

45. Secondary Outcome

Title	Cmax of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 2.50 mg/kg
Arm/Group Description	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0

46. Secondary Outcome

Title	Trough Plasma Concentration (Ctrough) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time Frame	Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	3	6
Day 1, Cycle 1,n=0,1,4,2,1,3,3,2,6	NA (NA)	381.95 (105.55)	1331.11 (44.43)	4307.00 (NA)	3720.27 (113.71)	11420.61 (35.70)	28134.46 (35.97)	2301.18 (75.69)
Day 1, Cycle 2,n=0,1,0,2,1,2,2,2,5	NA (NA)	1672.18 (28.76)	7259.00 (NA)	9510.04 (104.56)	12791.83 (46.82)	12719.77 (6.21)	2643.94 (123.56)

47. Secondary Outcome

Title	Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population.Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 1: GSK2857916 2.50 mg/kg
Arm/Group Description	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	8
Day 1, Cycle 1,n=8	3726.78 (49.92)
Day 1, Cycle 2,n=4	11352.94 (268.64)
Day 1, Cycle 4,n=3	11121.73 (59.75)

48. Secondary Outcome

Title	Terminal Half-life (t1/2) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time Frame	Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0	1	4	3	3	2	1	0	4
Geometric Mean (Geometric Coefficient of Variation) [Hours]	126.18 (NA)	188.20 (37.41)	117.82 (76.00)	198.48 (50.42)	264.93 (46.73)	308.39 (NA)	103.74 (17.29)

49. Secondary Outcome

Title	t1/2 of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 2.50 mg/kg
Arm/Group Description	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0

50. Secondary Outcome

Title	Volume of Distribution at Steady State (Vss) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time Frame	Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0	1	4	3	3	2	1	0	4
Geometric Mean (Geometric Coefficient of Variation) [Milliliter]	5239 (NA)	2900 (29.04)	4286 (31.29)	4388 (21.99)	3224 (22.37)	5156 (NA)	5215 (19.41)

51. Secondary Outcome

Title	Vss of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 2.50 mg/kg
Arm/Group Description	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0

52. Secondary Outcome

Title	Time to Reach Maximum Observed Concentration (Tmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
Time Frame	Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	3	3	3	3	6
Median (Full Range) [Hours]	2.080	4.080	1.185	3.085	1.000	2.050	1.000	6.920	1.560

53. Secondary Outcome

Title	Tmax of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 2.50 mg/kg
Arm/Group Description	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0

54. Secondary Outcome

Title	Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM-Part 2
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)

Outcome Measure Data

Analysis Population Description

PK Part 2 MM Population comprised of Part 2 MM participants of All Treated Population who had atleast 1 non-missing (NQ) PK assessment. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (MM)
Arm/Group Description	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
Measure Participants	35
Day 1, Cycle 1,n=28	3486.49 (85.71)
Day 1, Cycle 2,n=18	5799.89 (66.52)
Day 1, Cycle 4,n=12	6184.46 (103.79)

55. Secondary Outcome

Title	Ctrough of GSK2857916 Following IV Dose in Participants With NHL-Part 2
Description	Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 3)

Outcome Measure Data

Analysis Population Description

Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).
Measure Participants	5
Cycle 1 Day 1, n=5	0.0 (0.00)
Cycle 2 Day 1, n=4	3761.8 (2225.57)
Cycle 3 Day 1, n=1	8401.0 (NA)

56. Secondary Outcome

Title	AUC(0-tlast) of Cys Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
Description	Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time Frame	Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0	0	1	4	3	3	3	3	6
Geometric Mean (Geometric Coefficient of Variation) [Hours*picogram per milliliter]	1157.46 (NA)	1623.87 (41.43)	14681.62 (91.88)	20787.48 (209.27)	72608.00 (17.60)	119177.30 (35.77)	181147.61 (94.32)

57. Secondary Outcome

Title	AUC(0-tlast) of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Description	Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 2.50 mg/kg
Arm/Group Description	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0

58. Secondary Outcome

Title	Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
Description	Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time Frame	Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0	0	1	4	3	3	3	3	6
Geometric Mean (Geometric Coefficient of Variation) [Picograms per milliliter]	51.50 (NA)	91.49 (31.76)	260.62 (15.70)	488.29 (38.51)	1054.02 (18.96)	1199.86 (35.11)	2544.02 (87.04)

59. Secondary Outcome

Title	Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Description	Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 2.50 mg/kg
Arm/Group Description	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0

60. Secondary Outcome

Title	Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
Description	Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Time Frame	Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	3	6
Day 1, Cycle 1,n=0,1,4,2,1,3,3,2,6	NA (NA)	NA (NA)	NA (NA)	NA (NA)	NA (NA)	NA (NA)	NA (NA)	NA (NA)
Day 1, Cycle 2,n=0,1,0,2,1,2,2,2,5	NA (NA)	NA (NA)	NA (NA)	NA (NA)	NA (NA)	NA (NA)	NA (NA)

61. Secondary Outcome

Title	Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Description	Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 1: GSK2857916 2.50 mg/kg
Arm/Group Description	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	8
Day 1, Cycle 1,n=8	NA (NA)
Day 1, Cycle 2,n=4	NA (NA)
Day 1, Cycle 4,n=3	NA (NA)

62. Secondary Outcome

Title	Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
Description	Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
Time Frame	Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0	0	1	4	3	3	3	3	6
Median (Full Range) [Hours]	49.130	23.875	24.730	9.050	8.750	23.700	24.040

63. Secondary Outcome

Title	Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM-Part 1: GSK2857916 2.50 mg/kg
Description	Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
Time Frame	Pre-dose and EOI of Day 1 (Cycle 1)

Outcome Measure Data

Analysis Population Description

PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 1: GSK2857916 2.50 mg/kg
Arm/Group Description	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	0

64. Secondary Outcome

Title	Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 1
Description	Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated electrochemiluminescent (ECL) immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.
Time Frame	Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 1 Population

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	8	3	6
Count of Participants [Participants]	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%

65. Secondary Outcome

Title	Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (MM)
Description	Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.
Time Frame	Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 MM Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (MM)
Arm/Group Description	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
Measure Participants	33
Count of Participants [Participants]	0 0%

66. Secondary Outcome

Title	Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (NHL)
Description	Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated ECLimmunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.
Time Frame	Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

Outcome Measure Data

Analysis Population Description

Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).
Measure Participants	5
Count of Participants [Participants]	0 0%

67. Secondary Outcome

Title	Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Description	Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive (pos) samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative (neg) conclusive ADA results at Baseline and different timepoints is presented.
Time Frame	Baseline, Day 1 (Cycle 2, 3, 4, 6, 9, 12, 16), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)

Outcome Measure Data

Analysis Population Description

Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	8	3	6
Baseline,screening,pos, n=1,1,4,4,4,3,4,7,2,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Baseline,screening,neg, n=1,1,4,4,4,3,4,7,2,6	1 100%	1 100%	4 100%	4 100%	4 100%	3 100%	4 100%	7 87.5%	2 66.7%	6 100%
Baseline,neg,conclusive,n=1,1,4,4,4,3,4,7,2,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	6 75%	0 0%	0 0%
Cycle 2 Day 1,screening,pos, n=0,1,4,2,2,3,3,8,3,5	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Cycle 2 Day 1,screening,neg, n=0,1,4,2,2,3,3,8,3,5	1 100%	4 400%	2 50%	2 50%	3 75%	3 100%	8 200%	3 37.5%	5 166.7%
Cycle 2 Day 1,neg,conclusive,n=0,1,4,2,2,3,3,8,3,5	1 100%	3 300%	2 50%	2 50%	3 75%	3 100%	8 200%	2 25%	5 166.7%
Cycle 3 Day 1,screening,pos, n=0,1,0,2,2,1,2,4,3,6	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Cycle 3 Day 1,screening,neg, n=0,1,0,2,2,1,2,4,3,6	1 100%	2 200%	2 50%	1 25%	2 50%	4 133.3%	3 75%	6 75%
Cycle 3 Day 1,neg,conclusive,n=0,1,0,2,2,1,2,4,3,6	1 100%	2 200%	2 50%	1 25%	2 50%	2 66.7%	0 0%	4 50%
Cycle 4 Day 1,screening,pos, n=0,0,0,0,0,0,0,0,0,1	0 0%
Cycle 4 Day 1,screening,neg, n=0,0,0,0,0,0,0,0,0,1	1 100%
Cycle 4 Day 1,neg,conclusive,n=0,0,0,0,0,0,0,0,0,1	0 0%
Cycle 6 Day 1,screening,pos, n=0,0,0,1,1,1,2,3,3,3	0 0%	0 0%	0 0%	0 0%	0 0%	1 33.3%	0 0%
Cycle 6 Day 1,screening,neg, n=0,0,0,1,1,1,2,3,3,3	1 100%	1 100%	1 25%	2 50%	3 75%	2 66.7%	3 75%
Cycle 6 Day 1,confirming,pos,n=0,0,0,0,0,0,0,0,1,0	0 0%
Cycle 6 Day 1,confirming,neg,n=0,0,0,0,0,0,0,0,1,0	1 100%
Cycle 6 Day 1,neg,conclusive,n=0,0,0,1,1,1,2,3,3,3	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Cycle 9 Day 1,screening,pos, n=0,0,0,1,0,0,1,1,2,2	0 0%	0 0%	0 0%	0 0%	0 0%
Cycle 9 Day 1,screening,neg, n=0,0,0,1,0,0,1,1,2,2	1 100%	1 100%	1 25%	2 50%	2 50%
Cycle 9 Day 1,neg,conclusive,n=0,0,0,1,0,0,1,1,2,2	0 0%	0 0%	0 0%	0 0%	0 0%
Cycle 12 Day 1,screening,pos,n=0,0,0,1,0,0,1,1,1,3	0 0%	0 0%	0 0%	0 0%	1 25%
Cycle 12 Day 1,screening,neg,n=0,0,0,1,0,0,1,1,1,3	1 100%	1 100%	1 25%	1 25%	2 50%
Cycle 12 Day1,confirming,pos,n=0,0,0,0,0,0,0,0,0,1	0 0%
Cycle 12 Day1,confirming,neg,n=0,0,0,0,0,0,0,0,0,1	1 100%
Cycle 12 Day1,neg,conclusive,n=0,0,0,1,0,0,1,1,1,3	0 0%	0 0%	0 0%	0 0%	0 0%
Cycle 16 Day 1,screening,pos,n=0,0,0,0,0,0,1,1,1,2	0 0%	0 0%	0 0%	0 0%
Cycle 16 Day 1,screening,neg,n=0,0,0,0,0,0,1,1,1,2	1 100%	1 100%	1 25%	2 50%
Cycle 16 Day1,neg,conclusive,n=0,0,0,0,0,0,1,1,1,2	0 0%	0 0%	0 0%	0 0%
End of study,screening,pos,n=1,1,4,4,4,3,3,6,1,5	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
End of study,screening,neg,n=1,1,4,4,4,3,3,6,1,5	1 100%	1 100%	4 100%	3 75%	4 100%	3 100%	3 75%	6 75%	1 33.3%	5 83.3%
End of study,confirming,pos,n=0,0,0,1,0,0,0,0,0,0	0 0%
End of study,confirming,neg,n=0,0,0,1,0,0,0,0,0,0	1 100%
End of study,neg,conclusive,n=1,1,4,4,4,3,3,6,1,5	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%

68. Secondary Outcome

Title	Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Description	Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.
Time Frame	Baseline, Day 1 (Cycle 2, 3, 6, 7, 9, 11, 12, 16), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)

Outcome Measure Data

Analysis Population Description

Part 2 MM Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (MM)
Arm/Group Description	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
Measure Participants	35
Baseline, screening, positive, n=30	2 200%
Baseline, screening, negative n=30	28 2800%
Baseline, confirming, positive, n=2	0 0%
Baseline, confirming, negative, n=2	2 200%
Baseline, negative, conclusive, n=30	21 2100%
Cycle 2, Day 1, screening, positive, n=31	3 300%
Cycle 2, Day 1, screening, negative, n=31	28 2800%
Cycle 2, Day 1, confirming, positive, n=3	0 0%
Cycle 2, Day 1, confirming, negative, n=3	3 300%
Cycle 2, Day 1, negative, conclusive, n=31	27 2700%
Cycle 3, Day 1, screening, positive, n=23	0 0%
Cycle 3, Day 1, screening, negative, n=23	23 2300%
Cycle 3, Day 1, negative, conclusive, n=23	14 1400%
Cycle 6, Day 1, screening, positive, n=17	4 400%
Cycle 6, Day 1, screening, negative, n=17	13 1300%
Cycle 6, Day 1, confirming, positive, n=4	0 0%
Cycle 6, Day 1, confirming, negative, n=4	4 400%
Cycle 6, Day 1, negative, conclusive, n=17	0 0%
Cycle 7, Day 1, screening, positive, n=1	0 0%
Cycle 7, Day 1, screening, negative, n=1	1 100%
Cycle 7, Day 1, negative, conclusive, n=1	0 0%
Cycle 9, Day 1, screening, positive, n=16	2 200%
Cycle 9, Day 1, screening, negative, n=16	14 1400%
Cycle 9, Day 1, confirming, positive, n=2	0 0%
Cycle 9, Day 1, confirming, negative, n=2	2 200%
Cycle 9, Day 1, negative, conclusive, n=16	0 0%
Cycle 11, Day 1, screening, positive, n=1	0 0%
Cycle 11, Day 1, screening, negative, n=1	1 100%
Cycle 11, Day 1, negative, conclusive, n=1	0 0%
Cycle 12, Day 1, screening, positive, n=8	0 0%
Cycle 12, Day 1, screening, negative, n=8	8 800%
Cycle 12, Day 1, negative, conclusive, n=8	0 0%
Cycle 16, Day 1, screening, positive, n=8	0 0%
Cycle 16, Day 1, screening, negative, n=8	8 800%
Cycle 16, Day 1, negative, conclusive, n=8	0 0%
End of study, screening, positive, n=21	1 100%
End of study, screening, negative, n=21	20 2000%
End of study, confirming, positive, n=1	0 0%
End of study, confirming, negative, n=1	1 100%
End of study, negative, conclusive, n=21	0 0%

69. Secondary Outcome

Title	Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
Description	Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.
Time Frame	Baseline, Day 1 (Cycle 2, 3), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)

Outcome Measure Data

Analysis Population Description

Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).
Measure Participants	5
Baseline, screening, positive, n=5	0 0%
Baseline, screening, negative n=5	5 500%
Baseline, negative, conclusive, n=5	5 500%
Cycle 2, Day 1, screening, positive, n=4	0 0%
Cycle 2, Day 1, screening, negative, n=4	4 400%
Cycle 2, Day 1, negative, conclusive, n=4	4 400%
Cycle 3, Day 1, screening, positive, n=2	1 100%
Cycle 3, Day 1, screening, negative, n=2	1 100%
Cycle 3, Day 1, confirming, positive, n=1	0 0%
Cycle 3, Day 1, confirming, negative, n=1	1 100%
Cycle 3, Day 1, negative, conclusive, n=2	1 100%
End of study, screening, positive, n=4	0 0%
End of study, screening, negative, n=4	4 400%
End of study, negative, conclusive, n=4	0 0%

70. Secondary Outcome

Title	Overall Response Rate (ORR)- Part 1
Description	ORR was determined by the investigator according to international myeloma working group uniform response criteria for MM (IMWG 2011). ORR was calculated as the number of participants with best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR).
Time Frame	From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 21.6 months)

Outcome Measure Data

Analysis Population Description

Part 1 Population

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	8	3	6
Count of Participants [Participants]	0 0%	0 0%	0 0%	0 0%	0 0%	1 33.3%	1 25%	1 12.5%	3 100%	3 50%

71. Secondary Outcome

Title	ORR-Part 2 (MM)
Description	ORR was determined by the investigator according to IMWG 2011 uniform response criteria for MM. ORR was calculated as the number of participants with best overall response of sCR, CR, VGPR and PR.
Time Frame	From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 24.2 months)

Outcome Measure Data

Analysis Population Description

Part 2 MM Population

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (MM)
Arm/Group Description	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
Measure Participants	35
Count of Participants [Participants]	21 2100%

72. Secondary Outcome

Title	ORR-Part 2 (NHL)
Description	Overall Response Rate in NHL population was determined by the investigator according to Revised Response Criteria for Malignant Lymphoma. ORR was calculated as the number of participants with confirmed complete remission (CR) or partial remission (PR). Complete remission was defined as disappearance of all evidence of disease and partial remission was defined as regression of measurable disease and no new sites.
Time Frame	From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 7.2 months)

Outcome Measure Data

Analysis Population Description

Part 2 NHL Population

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).
Measure Participants	6
Count of Participants [Participants]	0 0%

73. Secondary Outcome

Title	Clinical Benefit Rate (CBR)- Part 1
Description	CBR was calculated as the number of participants with best overall response of sCR, CR, VGPR, PR and minimal response (MR).
Time Frame	From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 21.6 months)

Outcome Measure Data

Analysis Population Description

Part 1 Population

Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg	Part 1: GSK2857916 0.06 mg/kg	Part 1: GSK2857916 0.12 mg/kg	Part 1: GSK2857916 0.24 mg/kg	Part 1: GSK2857916 0.48 mg/kg	Part 1: GSK2857916 0.96 mg/kg	Part 1: GSK2857916 1.92 mg/kg	Part 1: GSK2857916 2.50 mg/kg	Part 1: GSK2857916 3.40 mg/kg	Part 1: GSK2857916 4.60 mg/kg
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).	Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
Measure Participants	1	1	4	4	4	3	4	8	3	6
Count of Participants [Participants]	0 0%	0 0%	0 0%	1 25%	1 25%	1 33.3%	2 50%	2 25%	3 100%	5 83.3%

74. Secondary Outcome

Title	CBR- Part 2
Description	CBR was calculated as the number of participants with best overall response of sCR, CR, VGPR, PR and MR.
Time Frame	From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 24.2 months)

Outcome Measure Data

Analysis Population Description

Part 2 MM Population. Data is presented only for Part 2 MM Population; since this analysis was not planned for Part 2 NHL Population.

Arm/Group Title	Part 2: GSK2857916 3.40 mg/kg (MM)
Arm/Group Description	Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
Measure Participants	35
Count of Participants [Participants]	21 2100%

Adverse Events

Time Frame	SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
Adverse Event Reporting Description	SAEs and common (>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
Arm/Group Title	Part 1: GSK2857916 0.03 mg/kg		Part 1: GSK2857916 0.06 mg/kg		Part 1: GSK2857916 0.12 mg/kg		Part 1: GSK2857916 0.24 mg/kg		Part 1: GSK2857916 0.48 mg/kg		Part 1: GSK2857916 0.96 mg/kg		Part 1: GSK2857916 1.92 mg/kg		Part 1: GSK2857916 2.50 mg/kg		Part 1: GSK2857916 3.40 mg/kg		Part 1: GSK2857916 4.60 mg/kg		Part 2: GSK2857916 3.40 mg/kg (MM)		Part 2: GSK2857916 3.40 mg/kg (NHL)
Arm/Group Description	Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).		Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).		Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).		Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).		Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).		Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).		Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).		Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).		Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).		Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).		Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).		Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).
All Cause Mortality
	Part 1: GSK2857916 0.03 mg/kg		Part 1: GSK2857916 0.06 mg/kg		Part 1: GSK2857916 0.12 mg/kg		Part 1: GSK2857916 0.24 mg/kg		Part 1: GSK2857916 0.48 mg/kg		Part 1: GSK2857916 0.96 mg/kg		Part 1: GSK2857916 1.92 mg/kg		Part 1: GSK2857916 2.50 mg/kg		Part 1: GSK2857916 3.40 mg/kg		Part 1: GSK2857916 4.60 mg/kg		Part 2: GSK2857916 3.40 mg/kg (MM)		Part 2: GSK2857916 3.40 mg/kg (NHL)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/1 (0%)		0/1 (0%)		0/4 (0%)		0/4 (0%)		0/4 (0%)		0/3 (0%)		0/4 (0%)		1/8 (12.5%)		0/3 (0%)		1/6 (16.7%)		5/35 (14.3%)		3/6 (50%)
Serious Adverse Events
	Part 1: GSK2857916 0.03 mg/kg		Part 1: GSK2857916 0.06 mg/kg		Part 1: GSK2857916 0.12 mg/kg		Part 1: GSK2857916 0.24 mg/kg		Part 1: GSK2857916 0.48 mg/kg		Part 1: GSK2857916 0.96 mg/kg		Part 1: GSK2857916 1.92 mg/kg		Part 1: GSK2857916 2.50 mg/kg		Part 1: GSK2857916 3.40 mg/kg		Part 1: GSK2857916 4.60 mg/kg		Part 2: GSK2857916 3.40 mg/kg (MM)		Part 2: GSK2857916 3.40 mg/kg (NHL)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/1 (0%)		0/1 (0%)		1/4 (25%)		1/4 (25%)		1/4 (25%)		0/3 (0%)		2/4 (50%)		4/8 (50%)		1/3 (33.3%)		3/6 (50%)		17/35 (48.6%)		3/6 (50%)
Blood and lymphatic system disorders
Febrile neutropenia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Hyperviscosity syndrome	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Neutropenia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Thrombocytopenia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Anaemia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
Cardiac disorders
Atrial fibrillation	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Pericardial effusion	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Eye disorders
Limbal stem cell deficiency	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Retinal detachment	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	2	0/6 (0%)	0
Gastrointestinal disorders
Nausea	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Vomiting	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Abdominal pain	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
General disorders
Pain	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Pyrexia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	1/35 (2.9%)	1	0/6 (0%)	0
Non-cardiac chest pain	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
Infections and infestations
Adenovirus infection	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Appendicitis	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Babesiosis	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Bacteraemia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Cholecystitis infective	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Gastroenteritis salmonella	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Influenza	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Lower respiratory tract infection	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Pneumonia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	1/3 (33.3%)	1	0/6 (0%)	0	5/35 (14.3%)	5	0/6 (0%)	0
Pneumonia haemophilus	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Respiratory tract infection	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Salmonellosis	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Infection	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
Injury, poisoning and procedural complications
Fall	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Infusion related reaction	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Metabolism and nutrition disorders
Hypercalcaemia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	1/6 (16.7%)	1
Musculoskeletal and connective tissue disorders
Arthralgia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Back pain	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Pathological fracture	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Malignant melanoma in situ	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Nervous system disorders
Encephalopathy	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Haemorrhage intracranial	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Spinal cord compression	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Renal and urinary disorders
Haematuria	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	1/35 (2.9%)	1	0/6 (0%)	0
Respiratory, thoracic and mediastinal disorders
Pharyngeal haemorrhage	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Vascular disorders
Deep vein thrombosis	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Hypotension	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Other (Not Including Serious) Adverse Events
	Part 1: GSK2857916 0.03 mg/kg		Part 1: GSK2857916 0.06 mg/kg		Part 1: GSK2857916 0.12 mg/kg		Part 1: GSK2857916 0.24 mg/kg		Part 1: GSK2857916 0.48 mg/kg		Part 1: GSK2857916 0.96 mg/kg		Part 1: GSK2857916 1.92 mg/kg		Part 1: GSK2857916 2.50 mg/kg		Part 1: GSK2857916 3.40 mg/kg		Part 1: GSK2857916 4.60 mg/kg		Part 2: GSK2857916 3.40 mg/kg (MM)		Part 2: GSK2857916 3.40 mg/kg (NHL)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1/1 (100%)		1/1 (100%)		4/4 (100%)		4/4 (100%)		3/4 (75%)		3/3 (100%)		4/4 (100%)		8/8 (100%)		3/3 (100%)		6/6 (100%)		35/35 (100%)		6/6 (100%)
Blood and lymphatic system disorders
Anaemia	0/1 (0%)	0	1/1 (100%)	1	1/4 (25%)	1	1/4 (25%)	1	0/4 (0%)	0	2/3 (66.7%)	4	1/4 (25%)	1	3/8 (37.5%)	3	0/3 (0%)	0	3/6 (50%)	4	10/35 (28.6%)	12	1/6 (16.7%)	1
Increased tendency to bruise	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Lymphopenia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Neutropenia	1/1 (100%)	1	1/1 (100%)	2	1/4 (25%)	1	1/4 (25%)	1	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	1/6 (16.7%)	1	2/35 (5.7%)	3	0/6 (0%)	0
Thrombocytopenia	1/1 (100%)	1	1/1 (100%)	1	1/4 (25%)	1	1/4 (25%)	1	1/4 (25%)	7	0/3 (0%)	0	1/4 (25%)	1	1/8 (12.5%)	1	2/3 (66.7%)	4	5/6 (83.3%)	9	9/35 (25.7%)	18	0/6 (0%)	0
Cardiac disorders
Atrial flutter	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Bradycardia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Bundle branch block left	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	2	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Bundle branch block right	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Sinus tachycardia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Tachycardia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Ventricular extrasystoles	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Ear and labyrinth disorders
Vertigo	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Endocrine disorders
Cushingoid	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Hypothyroidism	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Eye disorders
Borderline glaucoma	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Corneal deposits	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Corneal disorder	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Corneal irritation	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Corneal oedema	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Corneal opacity	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Diplopia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Dry eye	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	1/3 (33.3%)	1	2/4 (50%)	3	1/8 (12.5%)	1	2/3 (66.7%)	3	1/6 (16.7%)	1	13/35 (37.1%)	18	1/6 (16.7%)	1
Eye pain	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	4/35 (11.4%)	4	1/6 (16.7%)	1
Eye pruritus	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Foreign body sensation in eyes	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Keratitis	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	3/35 (8.6%)	3	1/6 (16.7%)	1
Keratopathy	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	2	0/3 (0%)	0	0/6 (0%)	0	3/35 (8.6%)	3	0/6 (0%)	0
Lacrimation increased	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	4/35 (11.4%)	6	0/6 (0%)	0
Ocular hypertension	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Ocular toxicity	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Optic disc haemorrhage	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Photophobia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	2	1/3 (33.3%)	3	2/6 (33.3%)	2	10/35 (28.6%)	11	0/6 (0%)	0
Photopsia	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Punctate keratitis	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	1/4 (25%)	1	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Vision blurred	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	3/4 (75%)	3	2/8 (25%)	2	3/3 (100%)	11	4/6 (66.7%)	4	18/35 (51.4%)	53	2/6 (33.3%)	3
Visual impairment	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/3 (0%)	0	2/4 (50%)	2	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Periorbital swelling	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
Gastrointestinal disorders
Abdominal distension	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Abdominal pain	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	1/6 (16.7%)	1	2/35 (5.7%)	2	0/6 (0%)	0
Angina bullosa haemorrhagica	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Constipation	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	1/6 (16.7%)	1	7/35 (20%)	8	1/6 (16.7%)	1
Diarrhoea	0/1 (0%)	0	1/1 (100%)	1	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	1/3 (33.3%)	1	1/6 (16.7%)	1	10/35 (28.6%)	11	1/6 (16.7%)	1
Dry mouth	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Dyspepsia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	3/35 (8.6%)	3	0/6 (0%)	0
Dysphagia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Gastrooesophageal reflux disease	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Gingival bleeding	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Hypoaesthesia oral	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Lip pain	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Nausea	0/1 (0%)	0	0/1 (0%)	0	2/4 (50%)	2	2/4 (50%)	2	1/4 (25%)	1	0/3 (0%)	0	3/4 (75%)	3	3/8 (37.5%)	3	2/3 (66.7%)	5	4/6 (66.7%)	4	11/35 (31.4%)	15	1/6 (16.7%)	1
Rectal haemorrhage	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Stomatitis	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Toothache	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Vomiting	0/1 (0%)	0	1/1 (100%)	1	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	2/6 (33.3%)	2	2/35 (5.7%)	3	0/6 (0%)	0
General disorders
Asthenia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Catheter site discharge	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Chest discomfort	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Chills	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	2	1/4 (25%)	1	0/4 (0%)	0	1/3 (33.3%)	1	2/4 (50%)	2	1/8 (12.5%)	1	2/3 (66.7%)	2	1/6 (16.7%)	1	9/35 (25.7%)	10	1/6 (16.7%)	1
Facial pain	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Fatigue	1/1 (100%)	1	0/1 (0%)	0	1/4 (25%)	1	2/4 (50%)	2	1/4 (25%)	3	2/3 (66.7%)	3	1/4 (25%)	1	3/8 (37.5%)	4	2/3 (66.7%)	2	4/6 (66.7%)	4	8/35 (22.9%)	9	1/6 (16.7%)	1
Gait disturbance	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	2	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Influenza like illness	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	3	0/35 (0%)	0	0/6 (0%)	0
Malaise	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
Oedema peripheral	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	3/35 (8.6%)	3	0/6 (0%)	0
Pain	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Pyrexia	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	1/4 (25%)	1	0/4 (0%)	0	1/3 (33.3%)	1	2/4 (50%)	2	0/8 (0%)	0	1/3 (33.3%)	1	2/6 (33.3%)	3	9/35 (25.7%)	13	0/6 (0%)	0
Hepatobiliary disorders
Jaundice	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
Infections and infestations
Alpha haemolytic streptococcal infection	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Babesiosis	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Bronchitis	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Conjunctivitis	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	1/3 (33.3%)	1	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Conjunctivitis viral	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Diverticulitis	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Influenza	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Lower respiratory tract infection bacterial	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Nasopharyngitis	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	3/35 (8.6%)	4	0/6 (0%)	0
Oral herpes	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Pneumonia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	1/6 (16.7%)	1	4/35 (11.4%)	5	0/6 (0%)	0
Rhinitis	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Sinusitis	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	5/35 (14.3%)	8	0/6 (0%)	0
Skin infection	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Tooth infection	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Upper respiratory tract infection	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	1/4 (25%)	1	1/3 (33.3%)	1	0/4 (0%)	0	1/8 (12.5%)	1	1/3 (33.3%)	1	1/6 (16.7%)	1	9/35 (25.7%)	12	0/6 (0%)	0
Urinary tract infection	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	4/35 (11.4%)	7	0/6 (0%)	0
Injury, poisoning and procedural complications
Contusion	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	1/3 (33.3%)	1	1/6 (16.7%)	1	5/35 (14.3%)	5	0/6 (0%)	0
Humerus fracture	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Infusion related reaction	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	1/3 (33.3%)	1	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Skin laceration	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Rib fracture	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Spinal compression fracture	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Spinal cord injury thoracic	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Investigations
Alanine aminotransferase increased	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	1/6 (16.7%)	2	7/35 (20%)	8	0/6 (0%)	0
Aspartate aminotransferase increased	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	1/8 (12.5%)	1	2/3 (66.7%)	3	4/6 (66.7%)	5	13/35 (37.1%)	17	0/6 (0%)	0
Blood alkaline phosphatase increased	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	5/35 (14.3%)	7	0/6 (0%)	0
Blood creatine phosphokinase increased	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	2/8 (25%)	2	1/3 (33.3%)	1	2/6 (33.3%)	2	3/35 (8.6%)	3	1/6 (16.7%)	1
Blood creatinine increased	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	2/35 (5.7%)	4	0/6 (0%)	0
Blood lactate dehydrogenase increased	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	1/8 (12.5%)	2	1/3 (33.3%)	1	2/6 (33.3%)	2	0/35 (0%)	0	1/6 (16.7%)	1
Gamma-glutamyltransferase increased	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	1/6 (16.7%)	1	7/35 (20%)	11	1/6 (16.7%)	1
Intraocular pressure increased	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	4/35 (11.4%)	4	0/6 (0%)	0
Lymphocyte count decreased	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	1/6 (16.7%)	1	3/35 (8.6%)	8	0/6 (0%)	0
Neutrophil count decreased	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	1/6 (16.7%)	1	3/35 (8.6%)	5	0/6 (0%)	0
Platelet count decreased	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	1/8 (12.5%)	1	1/3 (33.3%)	1	0/6 (0%)	0	13/35 (37.1%)	30	1/6 (16.7%)	1
White blood cell count decreased	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Blood immunoglobulin G decreased	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
Metabolism and nutrition disorders
Decreased appetite	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/3 (0%)	0	0/4 (0%)	0	2/8 (25%)	2	0/3 (0%)	0	1/6 (16.7%)	1	5/35 (14.3%)	6	0/6 (0%)	0
Dehydration	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Hypercalcaemia	0/1 (0%)	0	0/1 (0%)	0	2/4 (50%)	2	0/4 (0%)	0	0/4 (0%)	0	1/3 (33.3%)	1	2/4 (50%)	2	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	3/35 (8.6%)	3	0/6 (0%)	0
Hypercreatininaemia	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Hyperglycaemia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	1/6 (16.7%)	1	4/35 (11.4%)	10	0/6 (0%)	0
Hyperkalaemia	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Hyperuricaemia	0/1 (0%)	0	1/1 (100%)	1	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Hypoalbuminaemia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Hypokalaemia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	4/35 (11.4%)	5	0/6 (0%)	0
Hypomagnesaemia	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Hyponatraemia	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	1/8 (12.5%)	1	0/3 (0%)	0	2/6 (33.3%)	2	0/35 (0%)	0	0/6 (0%)	0
Hypophagia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Hypophosphataemia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Hyperphosphataemia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
Musculoskeletal and connective tissue disorders
Arthralgia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	2/4 (50%)	2	0/3 (0%)	0	1/4 (25%)	4	1/8 (12.5%)	1	0/3 (0%)	0	1/6 (16.7%)	1	4/35 (11.4%)	5	0/6 (0%)	0
Back pain	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	1/4 (25%)	1	0/3 (0%)	0	0/4 (0%)	0	2/8 (25%)	3	0/3 (0%)	0	1/6 (16.7%)	1	7/35 (20%)	7	0/6 (0%)	0
Bone pain	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Muscle spasms	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	3/35 (8.6%)	3	0/6 (0%)	0
Muscular weakness	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
Musculoskeletal chest pain	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	2/8 (25%)	3	0/3 (0%)	0	1/6 (16.7%)	1	4/35 (11.4%)	4	0/6 (0%)	0
Musculoskeletal pain	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Musculoskeletal stiffness	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Myalgia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	2/6 (33.3%)	2	2/35 (5.7%)	2	0/6 (0%)	0
Neck pain	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	2/8 (25%)	2	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Osteonecrosis of jaw	1/1 (100%)	1	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Pain in extremity	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	1/4 (25%)	1	1/4 (25%)	1	0/3 (0%)	0	1/4 (25%)	1	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	4/35 (11.4%)	4	0/6 (0%)	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
Nervous system disorders
Disturbance in attention	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Dizziness	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Taste disorder	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Facial nerve disorder	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Headache	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	1/8 (12.5%)	1	1/3 (33.3%)	3	2/6 (33.3%)	2	5/35 (14.3%)	5	0/6 (0%)	0
Hypoaesthesia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Migraine	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	2	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Neuropathy peripheral	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Paraesthesia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Peripheral sensory neuropathy	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Presyncope	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	3	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Restless legs syndrome	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Syncope	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Psychiatric disorders
Anxiety	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Depression	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
Insomnia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	3/35 (8.6%)	3	0/6 (0%)	0
Renal and urinary disorders
Albuminuria	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Haematuria	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
Micturition urgency	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Nocturia	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Proteinuria	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	2/35 (5.7%)	3	0/6 (0%)	0
Urinary tract pain	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Pollakiuria	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	1/6 (16.7%)	1
Respiratory, thoracic and mediastinal disorders
Cough	0/1 (0%)	0	0/1 (0%)	0	2/4 (50%)	2	1/4 (25%)	1	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	2/8 (25%)	3	2/3 (66.7%)	3	0/6 (0%)	0	14/35 (40%)	16	1/6 (16.7%)	1
Dyspnoea	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	6/35 (17.1%)	6	0/6 (0%)	0
Dyspnoea exertional	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Epistaxis	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	1/4 (25%)	1	1/3 (33.3%)	1	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	2/6 (33.3%)	2	3/35 (8.6%)	4	0/6 (0%)	0
Nasal congestion	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Oropharyngeal pain	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	3/35 (8.6%)	4	0/6 (0%)	0
Productive cough	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Rhinitis allergic	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Upper-airway cough syndrome	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Skin and subcutaneous tissue disorders
Acne	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Decubitus ulcer	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Night sweats	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Petechiae	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Pruritus	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	3/8 (37.5%)	3	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Rash	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	1/3 (33.3%)	1	0/6 (0%)	0	4/35 (11.4%)	5	1/6 (16.7%)	1
Rash maculo-papular	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	3/35 (8.6%)	3	0/6 (0%)	0
Skin hypopigmentation	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Telangiectasia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	0/35 (0%)	0	0/6 (0%)	0
Alopecia	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	2/35 (5.7%)	2	0/6 (0%)	0
Vascular disorders
Embolism	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Flushing	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/8 (12.5%)	1	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0
Hypertension	0/1 (0%)	0	0/1 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/8 (0%)	0	0/3 (0%)	0	1/6 (16.7%)	1	3/35 (8.6%)	3	0/6 (0%)	0
Hypotension	0/1 (0%)	0	0/1 (0%)	0	1/4 (25%)	1	0/4 (0%)	0	0/4 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/8 (0%)	0	0/3 (0%)	0	0/6 (0%)	0	0/35 (0%)	0	0/6 (0%)	0

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.